Radius Health, Inc.  
Abaloparatide -SC Confidential  
Radius Health, Inc. (RADIUS)  
950 Winter  Street,  Waltham,  MA 02451 USA 
Abaloparatide -SC 
CLINICAL  STUDY PROTOCOL:  BA058-05- 020 
An Open-label, Single- arm, Multicenter Study to Evaluate the Early Effects of  
Abaloparatide on Tissue -based Indices  of Bone Formation and Resorption  
This study will be conducted according to the protocol  and in compliance  with  Good  Clinical 
Practice, the ethical principles stated in the Declaration of Helsinki, and other applicable  
regulatory requirements.  
Document  type:  Clinical Study  Protocol 
IND num
ber 73,176 
Version  number:  Amendment 2  - 05 November 2018 
Development  phase:  3 
Study  Site:  Multicenter  
Prot
ocol Version History 
Version  number  Version date  
Original  14 December  2017  
Amendment  1 9 February  2018  
Confidentiality  Statement  
The information in this document contains trade secrets and/or commercial information that are 
privileged or confidential and may not be disclosed unless such disclosure is required by 
applicable  law or regulations.  In any event, persons to whom the information  is disclosed  must be 
informed that the information is privileged or confidential and may not be further disclosed by 
them.  These restrictions on  disclosure will apply  equally  to all 
future  information  supplied to  you which  is indicated  as privileged or confidential. 
NCT # [STUDY_ID_REMOVED]
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  2 of 60  
  
 
STATEMENT OF COMPLIANCE  
The study will be carried out in accordance with Good Clinical Practice (GCP) as  
required by the following: United States (US) Code of Federal Regulations (CFR)  
applicable to clinical studies (Title 21 CFR Part 11, 50, 54, 56, 312, and International 
Conference on Harmonization (ICH) GCP Guideline E6  (R2)):  
In addition, I have read the study protocol titled “An Open- label, Single- arm, Multicenter  
Study to Evaluate the Early Effects of Abaloparatide on Tissue-based Indices of Bone Formation and Resorption, amendment 2 dated 05 November2018, and agree to the following: 
• To conduct this study in accordance with the  design and provisions of this  
protocol. 
• To await institutional review  board (IRB)  approval for the protocol and  
informed  consent (IC) before  initiating  enrollment into the study. 
• To ensure that the requirements for obtaining IC  are met and to obtain IC from  
subjects  before  their  enrollment into the study. 
• To provide sufficient and accurate financial disclosure and update information if any relevant changes occur during the investigation and for one year following the completion  of the study. 
• To collect and  record data as required  by this protocol into the case report  
form  (CRF).  
• To maintain  the confidentiality  of all  information  received or  developed in 
connection with this protocol. 
• To conduct this study in accordance with the International Conference on  
Harmonisation (ICH), the Declaration of Helsinki, and applicable regulatory requirements.  
• To permit study-related monitoring, audits, IRB review, and regulatory inspection(s) by providing direct access to source  data/documents. 
• To maintain study documentation for the period of time  required. 
• To report all adverse events (AEs) within the specified timeframe to Radius  
Health,  Inc. (RADIUS) or their designee.  
• To report  all serious AEs/incidents within  24 hours after becoming aware of 
the event to the Contract Research Organization and enter the data into the Electronic  Data Capture system.  
• To adhere to the publication policy of RADIUS for data collected during this study. 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  3 of 60  
  
     
 
   
 
  
Signature of Principal Investigator  Date  
    
 
   
 
Print  Name Site Number 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  4 of 60  
  
 
AMENDMENT  1 RATIONALE  
 
This amendment updates and supersedes BA058-05-020 Clinical Study Protocol dated 
14 December  2017 for all investigative  sites.  The key revisions are as follows:  
 
• Revised  inclusion criteria  for acceptable serum  25-hydroxyvitamin D values  
• Removed all references to the subject’s assessment of local tolerance after  
injection  
• Removed  vitamin  D and calcium  dose requirement  from  Month 3 and  Month 4 as 
shown in Table 1 . 
• Added BMD assessment  to Section 7.2.10 and  to Table 1. 
• Removed  references  to and discussion of “incident” vertebral  fractures  in 
Section  7.7.2. This assessment  tool will  not be included in the protocol 
The protocol was updated to reflect these changes and to correct administrative and  
consistency errors. Full details of changes are presented in the “Protocol Amendment 1 
Summary  of Changes”.  
 
AMENDMENT  2 RATIONALE  
This amendment updates and supersedes BA058-05-020 Amendment 1 Clinical Study  
Protocol dated  9 Feb 2018 for all investigative  sites. The key  revisions are as follows: 
• Calcium will be administered daily, with the exception of the days of 
administration  of demeclocycline and tetracycline where calcium  administration  
will be withheld. 
• Subjects whose laboratory tests do not fall within the specified ranges as detailed in the inclusion/exclusion criteria may have the samples redrawn and the tests repeated  within  30 days of the original test  date. If  upon reanalysis,  the values fall  
within  the inclusion/exclusion criteria, the subject may  enter  the study. 
• Added calcium  withholding days to  Figure 1. 
The protocol was updated to reflect these changes and to correct administrative and  
consistency errors. Full details of changes are presented in the “Protocol Amendment 2 
Summary  of Changes”.  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  5 of 60  
  
 
TABLE OF CONTENTS  
STATEMENT OF  COMPLIANCE  ................................................................................................. 2 
AMENDMENT  1 RATIONALE  ..................................................................................................... 4 
AMENDMENT  2 RATIONALE  ..................................................................................................... 4 
TABLE OF  CONTENTS  ................................................................................................................. 5 
LIST  OF ABBREVIATIONS  .......................................................................................................... 9 
1. PROTOCOL  SYNOPSIS  ........................................................................................... 12 
2. INTRODUCTION  ...................................................................................................... 18 
2.1. Background ................................................................................................................. 18 
2.2. Disease and Study Background .................................................................................. 18 
2.3. Quadruple Label Technique ....................................................................................... 19 
2.4. Bone Histomorphometry Results from Study BA058-05-003 ................................... 20 
2.5. Study Rationale  ........................................................................................................... 21 
2.6. Dose  Rationale  ............................................................................................................ 21 
3. STUDY OBJECTIVES AND ENDPOINTS .............................................................. 22 
3.1. Objectives  ................................................................................................................... 22 
3.2. Endpoints .................................................................................................................... 22 
4. STUDY DESIGN  ....................................................................................................... 23 
4.1. Description  of the Study Design  ................................................................................. 23 
5. SELECTION OF  STUDY POPULATION  ................................................................ 24 
5.1.
 Inclusion Criteria  ........................................................................................................ 24 
5.2. Exclusion Criteria  ....................................................................................................... 25 
5.3. Participant  Withdrawal or Termination  ...................................................................... 26 
5.3.1. Reasons  for Withdrawal  or Termination  .................................................................... 26 
5.3.2. Handling of Participant  Withdrawals or Terminations ............................................... 27 
5.4. Concomitant Medications  ........................................................................................... 27 
5.5. Prohibited Medications ............................................................................................... 28 
5.6. Premature Termination or Suspension of Study ......................................................... 28 
5.7. Temporary  Suspension of Treatment .......................................................................... 29 
5.7.1. Treatment  Algorithm in  Subjects Who Develop Hypercalcemia  ............................... 29 
6. STUDY DRUG ADMINISTRATION AND MANAGEMENT ................................ 30 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  6 of 60  
 6.1. Study Medication  ........................................................................................................ 30 
6.1.1. Abaloparatide .............................................................................................................. 30 
6.2. Packaging, Labeling  and Storage ............................................................................... 30 
6.2.1. Packaging  and Labeling  .............................................................................................. 30 
6.2.2. Storage ........................................................................................................................ 30 
6.3. Treatment  Assignment ................................................................................................ 30 
6.4. Dosing and Administration  ......................................................................................... 31 
6.5. Treatment  Compliance ................................................................................................ 31 
6.6. Study Drug  Accountability ......................................................................................... 32 
7. STUDY PROCEDURES AND SCHEDULE  ............................................................ 33 
7.1. Study Procedures  ........................................................................................................ 33 
7.2. Study Schedule ........................................................................................................... 33 
7.2.1. Schedule of Assessments  and Procedures .................................................................. 33 
7.2.2. Informed  Consent Process .......................................................................................... 37 
7.2.3. Assigning Subject Numbers ....................................................................................... 37 
7.2.4. Subject  and Disease Characteristics  ........................................................................... 37 
7.2.5. Screening  (Visit 1)  ...................................................................................................... 37 
7.2.6. Pretreatment  (Visit 2)  ................................................................................................. 38 
7.2.7. Treatment  Period  ........................................................................................................ 39 
7.2.8.
 Day 1 (Visit 3)  ............................................................................................................ 39 
7.2.9. Month 1 (Visit 4)  ........................................................................................................ 40 
7.2.10. Month 3/Early  Termination (Visit 5)  .......................................................................... 40 
7.2.11. Month 4 (Visit 6)  ........................................................................................................ 41 
7.2.12. Unscheduled Visit ....................................................................................................... 41 
7.3. Vital Signs and Physical Examinations ...................................................................... 41 
7.4. 12-Lead  Electrocardiogram  ........................................................................................ 42 
7.5. Laboratory Evaluations ............................................................................................... 42 
7.5.1. Clinical Laboratory Evaluations ................................................................................. 42 
7.5.2. Serum  Markers of Bone Metabolism .......................................................................... 43 
7.5.3. Specimen  Preparation, Handling and Storage ............................................................ 44 
7.6. Bone Biopsy Processing  Procedure ............................................................................ 44 
7.7. Imaging Procedures  .................................................................................................... 44 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  7 of 60  
 7.7.1. Dual Energy X- ray Absorptiometry  (DXA)  ............................................................... 44 
7.7.2. Clinical and Radiologic Evaluation of Fractures ........................................................ 44 
7.7.3. Treatment  and Imaging at Selected Sites  .................................................................... 45 
7.8. Discontinuation from the  Study .................................................................................. 45 
7.8.1. Withdrawal  of Consent ............................................................................................... 45 
7.8.2. Early  Study Termination  ............................................................................................. 46 
8. ADVERSE  EVENT  AND SERIOUS  ADVERSE  EVENT  
DOCUMENTATION  ................................................................................................. 47 
8.1. Evaluation of Safety ................................................................................................... 47 
8.1.1. Adverse Events ........................................................................................................... 47 
8.1.2. Serious Adverse Events .............................................................................................. 47 
8.1.3. Recording Adverse Events .......................................................................................... 48 
8.1.4. Serious Adverse Event (SAE) Reporting ................................................................... 50 
8.1.5. Follow-up of Adverse Events  ..................................................................................... 50 
8.1.6. Abuse, Misuse, Overdose, or Medication Error ......................................................... 50 
8.1.7. Regulatory Agency, Institutional Review  Board, Ethics  Committee  
and Site Reporting ...................................................................................................... 51 
8.2. Study Completion and Post-Study Treatment  ............................................................. 51 
8.3. Lost to Follow-up ....................................................................................................... 51 
9.
 STATISTICAL  CONSIDERATIONS  ....................................................................... 52 
9.1. Statistical Analysis Plan  ............................................................................................. 52 
9.2. Statistical Hypothesis .................................................................................................. 52 
9.3. Analysis Datasets  ........................................................................................................ 52 
9.3.1. Population for Analysis .............................................................................................. 52 
9.4. Description  of Statistical Methods  .............................................................................. 52 
9.4.1. General  Approach ....................................................................................................... 52 
9.4.2. Analysis of the Primary  Efficacy  Endpoint(s) ............................................................ 52 
9.4.3. Analysis of Secondary Endpoint(s) ............................................................................ 52 
9.4.4. Safety  Analyses ........................................................................................................... 53 
9.4.5. Adherence and Retention Analyses ............................................................................ 53 
9.4.6. Baseline Descriptive  Statistics  .................................................................................... 54 
9.4.7. Interim Analyses  ......................................................................................................... 54 
9.4.8. Tabulation of Individual Response Data  .................................................................... 54 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  8 of 60  
 9.5. Sample  Size Calculation  ............................................................................................. 54 
9.6. Measures  to Minimize  Bias  ........................................................................................ 54 
9.7. Enrollment/Randomization/Masking  Procedures  ....................................................... 54 
10. ADMINISTRATIVE  REQUIREMENTS  .................................................................. 55 
10.1. Ethical  Considerations ................................................................................................ 55 
10.2. Subject  Information and Informed Consent ............................................................... 55 
10.3. Investigator Compliance ............................................................................................. 55 
10.4. Access  to Records ....................................................................................................... 56 
10.5. Subject  Data Confidentiality  ....................................................................................... 56 
10.6. Research  Use of Stored  Human Samples,  Specimens, or Data  .................................. 56 
10.7. Data Quality  Assurance  .............................................................................................. 57 
10.8. Monitoring .................................................................................................................. 57 
10.9. Data Collection and Management Responsibilities  .................................................... 57 
10.10. Study Records Retention  ............................................................................................ 58 
10.11. Publication  and Data Sharing  Policy  .......................................................................... 58 
REFERENCES  .............................................................................................................................. 59 
 
LIST  OF TABLES  
Table 1: Schedule of Assessments  and Procedures  .................................................................. 34 
Table 2: Clinical Laboratory  Tests ............................................................................................ 43 
 
 
LIST  OF FIGURES  
Figure 1: BA058-05-020 Study Design, Including Schematic of Bone Biopsy 
Labeling  Procedure  ..................................................................................................... 23 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  9 of 60  
  
LIST  OF ABBREVIATIONS  
Abbreviation Term  
 
°C Degree Celsius  
°F Degree Fahrenheit  
µg Microgram  
µL Microliter  
µmol Micromole  
AE Adverse event  
ALT  Alanine aminotransferase 
AP Anterior posterior 
AST  Aspartate aminotransferase 
BFR/BS  Bone formation  rate 
BMD  Bone mineral density  
BMI  Body mass index  
BUN Blood urea nitrogen 
cAMP  Cyclic  adenosine monophosphate 
Cm Centimeter  
CPK  Creatine phosphokinase 
CRF  Case report form  
CRO  Contract  research  organization 
Ct.Po/Ct.Ar Cortical porosity  
s-CTX  Serum carboxy- terminal cross -linking telopeptide of type I 
collagen  
DXA  Dual energy  X-ray absorptiometry 
ECG  Electrocardiogram  
eCRF  Electronic  case report form  
EDC  Electronic  data capture  
ES/BS  Eroded surface  
FDA  Food and Drug Administration  
FSH Follicle -stimulating  hormone 
g Gram  
GCP  Good Clinical Practice  
GGT  Gamma -glutamyl transpeptidase 
GMP  Good Manufacturing Practice  
HIV Human  immunodeficiency virus infection 
IB Investigator's Brochure 
ICF Informed  consent form  
ICH International Conference on  Harmonization  
IRB Institutional Review Board  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  10 of 60  
  
 
Abbreviation Term  
 
IU International unit 
IV Intravenous 
kg Kilogram 
L Liter  
LDH  Lactate dehydrogenase 
MAR  Mineral  apposition rate 
MCH  Mean  corpuscular hemoglobin 
MCHC  Mean  corpuscular  hemoglobin concentration  
MCV  Mean corpuscular  volume 
MedDRA Medical  dictionary for regulatory activities  
MF/BS  Modeling- based  formation  
mg Milligram 
mL Milliliter  
mmHg  Millimeter  of mercury  
MS/BS  Mineralizing  surface  
ng Nanogram 
oMF/BS  Overflow  modeling- based  formation  
OS/BS  Osteoid  surface  
O.Th  Osteoid  thickness 
OV/BV Osteoid  volume 
PA Posterior- anterior  
PI Principal Investigator  
s-PINP  Serum  procollagen type I N propeptide 
pQCT  Peripheral  quantitative  computed tomography 
RANK Receptor  activator of  nuclear factor  kappa-B 
RBC  Red blood cell 
RmF/BS  Remodeling- based  formation  
SAE  Serious adverse event  
SAP Statistical Analysis Plan  
SC Subcutaneous 
SD Standard  deviation 
SERMs  Selective estrogen receptor  modulators 
SOC  System  organ class  
SOP Standard  operating procedure 
TEAEs  Treatment  emergent  adverse events  
TSH  Thyroid stimulating  hormone 
ULN  Upper limit of normal 
WBC  White  blood cells 
WHO  World  Health  Organization 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  11 of 60  
  
 
Abbreviation Term  
 
W.Th  Wall  thickness 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  12 of 60  
  
 
1. PROTOCOL SYNOPSIS 
 
Name  of Sponsor/Company:  
Radius Health,  Inc. (RADIUS)  
Name  of Investigational Product:  
Abaloparatide- SC 
Name  of Active  Ingredient:  
abaloparatide  
Title  of Study:  
An Open -label, Single- arm, Multicenter Study to Evaluate the Early Effects of Abaloparatide 
on Tissue-based Indices of Bone Formation and Resorption 
Study  center(s): Approximately  5 in the United  States 
Studied  period  (years):  
Estimated date first subject enrolled: April 2018 
Estimated  date last  subject  completed: January 2019 Phase  of development:  3 
Objectives:  
The objectives of  this study are to: 
1. Demonstrate the early effects of abaloparatide on tissue -based bone formation and 
resorption indices 
2. Assess the degree to which increased bone formation is achieved by modeling,  
remodeling, and  overflow bone formation 
3. Relate  the early  indices  of tissue- based  bone formation  and bone resorption  to those  
measured  using  biochemical  markers of  bone turnover. 
Endpoints:  
• Change from baseline to 3 months in dynamic indices of bone formation in the  
relevant  bone envelopes (cancellous, endocortical,  intracortical,  and periosteal)  
− Mineralizing  surface  (MS/BS)  
− Mineral  apposition rate (MAR)  
− Bone formation  rate (BFR/BS)  
• Structural  indices  in the relevant bone envelopes at Month 3 
− Cortical  porosity (Ct.Po/Ct.Ar)  
• Static  indices in  the relevant bone  envelopes at Month  3 
− Osteoid  volume (OV/BV)  
− Osteoid  surface (OS/BS)  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  13 of 60  
  
− Osteoid  thickness  (O.Th)  
− Wall thickness (W.Th)  
− Eroded surface (ES/BS)  
• Change from baseline to 3 months in special histomorphometric variables in the  
relevant bone envelopes  
− Remodeling, modeling, and overflow modeling- based  formation  (RmF/BS,  
MF/BS,  oMF/BS)  
• Change in serum procollagen type I N- terminal propeptide (s -PINP) and carboxy- 
terminal cross-linking telopeptide of type I collagen (s- CTX) from baseline to 1 and 3  
months 
• Correlations of tissue -based indices of bone formation and bone resorption with s- 
PINP  and s- CTX  
• Overall safety and tolerability of abaloparatide in postmenopausal women with  
osteoporosis.  
Methodology: 
This is an open-label, single- arm, multicenter study of postmenopausal women with 
osteoporosis.  The study is designed  to measure the early  effects of  abaloparatide on  
tissue -based bone formation using samples obtained by iliac crest bone biopsy after quadruple 
fluorochrome labeling. The study will consist of a Screening Period (up to 1 month), a 
Pretreatment Period (approximately 1 month), a Treatment Period (3 months), and a Month 4 
visit one month after the  last dose of study  medication.  Biopsies are to be  obtained at 3 
months of treatment  for the  following reasons:  
• This is the optimal time for changes in biochemical markers of bone turnover to 
predict changes in BMD after 18 months of treatment with abaloparatide (Radius, 
data on file).  
• Longer periods of time increase  the risk that the  initial  set of  labels will be  
resorbed,  which would seriously confound the results.  
• Comparisons to the 3-month results for teriparatide from the AVA Osteoporosis 
Study will be possible. 
There will be a sub -study at selected sites to collect pQCT  data and extend an additional  
3 months of study drug administration for  a total  of 6 months of  treatment.  
Details of the schedule of measurements,  endpoints and statistical  analysis methods will be  
described  in a separate document  for the sub-study. 
Numb er of subjects (planned):  
Approximately 25 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  14 of 60  
  
Diagnosis and main  criteria  for inclusion:  
Inclusion  Criteria  
Subjects must meet all of  the following criteria  to be eligible  to participate  in this study: 
1. The subject  is a healthy  ambulatory postmenopausal female  from  50 to 85 years of 
age (inclusive)  with osteoporosis. 
2. The subject has been postmenopausal for at least 5 years. Postmenopausal status will 
be established by a history of amenorrhea for at least 5 years and by an elevated  
follicle -stimulating  hormone (FSH) value of > 30 IU/L. 
3. The subject has a BMD T -score ≤ -2.5 at the lumbar spine (L1- L4) or hip (femoral 
neck or total hip) by Dual energy X- ray absorptiometry (DXA) or lumbar spine or  
hip BMD T- score < -2.0 with a h istory of low trauma vertebral, forearm, humerus, 
sacral, pelvic, hip, femoral, or tibial fracture sustained within 5 years prior to enrollment.  These  fractures  must be  documented  by radiograph or hospital report. 
4. The subject is in good general health as d etermined by medical history and physical 
examination (including vital signs), has a body mass index (BMI) of 18.5 to 33, inclusive, and is without evidence of clinically significant abnormality in the opinion of the Investigator. 
5. The subject has serum cal cium (albumin -corrected), PTH (1 -84), phosphorus, and  
alkaline phosphatase levels all within  the normal range  during the Screening Period.  
Any subject with an elevated alkaline phosphatase value, and who meets all other entry criteria, is required to have a normal bone- specific alkaline phosphatase result  
to be enrolled. 
6. The subject has serum 25 -hydroxyvitamin D values > 20 ng/mL and within the 
normal range. Subjects with serum 25-hydroxyvitamin D levels < 20 ng/ml may be 
treated  with vitamin D3 and re-tested once. 
7. The subject’s resting 12 -lead electrocardiogram (ECG) obtained during screening 
shows no  clinically  significant abnormality. 
8. The subject has  read,  understood, and signed  the written  informed  consent form.  
Exclusion Criteria  
Subjects with any of the following characteristics  are not eligible  to participate  in the study: 
General exclusion criteria.  
1. Presence of abnormalities  of the lumbar  spine  that would  prohibit  assessment of  
lumbar spine BMD, defined as having at least 2 radiologically evaluable vertebrae within  L1-L4. 
2. Unevaluable hip BMD or subjects who have undergone bilateral hip replacement  
(unilateral hip replacement  is acceptable).  
3. History of bone disorders (eg, Paget’s disease) other than postmenopausal 
osteoporosis. 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  15 of 60  
  
4. Clinically significant abnormality of serum hemoglobin, hematocrit, white blood  
cells (WBC)  and platelets,  coagulation, or usual serum  chemistry:  electrolytes,  renal  
function, liver function and serum  proteins 
5. Unexplained elevation of  serum  alkaline phosphatase. 
6. History  of radiotherapy (radiation  therapy), other  than radioiodine. 
7. History of bleeding disorder that would preclude a bone biopsy, in the opinion of the 
Investigator. 
8. History of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular, 
gastrointestinal, endocrine, central nervous system, hematologic or metabolic 
diseases,  or immunologic,  emotional and/or psychiatric  disturbances to a degree that 
would interfere with the interpretation of study data or compromise the safety of the 
subject. 
9. History of Cushing’s disease, hyperthyroidism, hypo- or hyperparathyroidism, or 
malabsorptive  syndromes within the  past year.  
10. History  of significantly  impaired  renal function (serum  creatinine >177 µmol/L  or 
> 2.0 mg/dL. If the serum creatinine is > 1.5 and ≤ 2.0 mg/dL, the calculated 
creatinine clearance (Cockcroft -Gault)  must  be ≥ 30 mL/min.  
11. History of any cancer within the past 5 years (other than basal cell or squamous 
cancer  of the skin).  
12. Histor y of osteosarcoma at any time, or a history of hereditary disorders which would 
predispose the subject  to osteosarcoma.  
13. History  of nephrolithiasis or urolithiasis  within  the past five years.  
14. Subjects known to be positive for hepatitis B, hepatitis C, human immunodeficiency virus infection (HIV-1 or HIV-2). Testing is not required in the absence of clinical 
signs  and symptoms  suggestive of HIV infection  or acute  or chronic hepatitis.  
Medication -related  exclusion criteria  
15. Known  history of hypersensitivity  to any of the test  materials,  related  compounds, or 
tetracyclines.  
16. Prior  treatment with  PTH  or PTHrP drugs, including abaloparatide. 
17. Prior treatment with IV bisphosphonates at any time, or oral bisphosphonates within 
the past three years. Subjects who had received a short course of oral bisphosphonate 
therapy (3 months or less) may be enrolled as long as the treatment occurred 6 or  
more  months prior to enrollment.  
18. Treatment  with  fluoride or strontium  in the five years prior  to the Screening  Period  or 
prior treatment with gallium nitrate, or with any unapproved bone- acting  
investigational agents at any time.  
19. Treatment  with  calcitonin,  SERMs (such  as raloxifene  or tamoxifen),  or tibolone, in 
the past 6 months prior  to the Screening  Period. Estrogens administered  as hormone 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  16 of 60  
  
replacement  therapy  with or without  progestins  are not exclusionary.  
20. Treatment with anticonvulsants that affect vitamin D metabolism (phenobarbital,  
phenytoin, carbamazepine  or primidone) or with  chronic  heparin within  the 6 months 
prior  to the Screening Period.  
21. Prior  treatment  with  denosumab. 
22. Daily treatment with oral, intranasal or inhaled corticosteroids within the 12 months 
prior  to the Screening  Period.  Occasional  use of corticosteroids (for seasonal  allergies 
or asthma)  is not exclusionary. 
23. Prior treatment with anabolic steroids or calcineurin inhibitors (cyclosporin,  
tacrolimus).  
24. Exposure to an investigational drug within the 12 months prior to the Screening 
Period. 
Lifestyle -related  exclusion criteria  
25. Abnormal nutritional  status  (abnormal diets,  excessive or unusual vitamin  or herbal  
intakes,  malabsorption, significant  recent weight change),  vitamin  D intake of 
≥ 4,000 IU/day  or vitamin  A intake  of ≥ 10,000 IU/day. 
26. Subject is known to abuse alcohol or use illegal drugs within 12 months of the 
Screening Period. 
Investigational product,  dosage and mode  of administration:  
Abaloparatide 80  µg for subcutaneous injection  
Duration of treatment:  
3 months; 6 months  at selected sites  in the sub -study 
Reference therapy,  dosage and  mode  of administration:  
Not applicable  
Duration of Subject  Participation 
Participation will be up to 6 months (3 months total treatment duration; 6 months total 
treatment for  subjects  at selected sites  in the sub-study). 
Statistical  methods:  
Subject demographics and baseline characteristics will be summarized  using descriptive 
statistics.  
Sample size 
A sample size of 21 completers will provide at least 90% power to detect a statistically  
significant change from baseline in cancellous MS/BS (%) for abaloparatide at 3 months of  
9.2%, assuming a standard deviation of 12.0%. The study is planned to enroll approximately 25 subjects to accommodate a drop- out rate of 15%, including those with non-evaluable bone 
biopsy. Additional subjects may be enrolled if the number of evaluable biopsies is insufficient to achieve this power.  
Analysis population 
The primary  population  for all efficacy  analyses will  be the Bone -Biopsy Population, which  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  17 of 60  
  
is defined as all enrolled subjects who received a biopsy. The primary population for all  
safety analyses will be the Safety Population, which will be defined as all enrolled subjects 
who received at  least  one dose of  abaloparatide.  
Efficacy  analysis  
The primary endpoint of this study is the change from baseline to 3 months in mineralizing surface (MS/BS) in the cancellous bone envelope. Paired t- tests will be used to compare the 
differences in dynamic indices between the two time -points derived from the two sets of 
double labels using the Bone-Biopsy Population. If the normality assumption of efficacy 
variable is not satisfied at the 0.01 significance level and if visual inspection of the data 
deems it necessar y, an appropriate nonparametric test, such as the Wilcoxon signed-rank test, 
will be used to evaluate the primary endpoint. No adjustments for multiplicity will be made. A p-value < 0.05 will be considered  statistically  significant.  
The change and percent change in s -PINP and s -CTX from baseline will be summarized  
descriptively. The relationship between bone turnover markers and histomorphometric parameters  will be explored  using the linear regression  method. 
Safety 
Safety  analyses  will be descriptive in nature  and will include incidence  and severity  of 
adverse events and abnormalities in clinical laboratory tests, vital signs, ECGs, and  
Investigator assessment of local tolerance. All adverse events prior to the first dose of  
abaloparatide will  be summarized  separately.  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  18 of 60  
  
 
2. INTRODUCTION 
2.1. Background  
Abaloparatide (marketed as TYMLOS™ in the United States) is a novel, synthetic, 34 
amino acid peptide designed to be a potent and selective activator of the PTH/PTH- 
related protein (PTHrP) type 1 receptor (PTHR 1) signaling pathway with 41% homology 
to PTH[1 –34]) and 76% homology to human PTHrP[1–34]. Abaloparatide is 
differentiated from PTH and PTHrP ligands based on its high affinity and > 1000- fold 
greater  selectivity  for the G protein-coupled (RG) vs the non-G protein-coupled (R0) 
conformation of PTHR 1 (Hattersley, 2016). Differential PTHR 1-RG binding with 
abaloparatide results  in potent and  transient  intracellular  cyclic AMP  (cAMP)  signaling. 
In nonclinical studies, the  transient  PTHR 1 activation  with  abaloparatide strongly favors  
bone anabolism with a limited  effect on bone resorption ( Makino, 2015).  
Abaloparatide is approved in the United States for the treatment of postmenopausal 
women with osteoporosis at high risk for fracture. Abaloparatide was shown in Study BA058-05-003 (ACTIVE) to reduce the risk of vertebral and nonvertebral fractures compared  to placebo, and  to increase hip BMD  more  than teriparatide  (Miller,  2016).  
 
2.2. Disease  and Study  Background  
Osteoporosis is a systemic skeletal disease characterized by low bone mass and  
microarchitectural deterioration of bone tissue that leads to enhanced fragility and increased  risk of fractures  (Rizzoli,  2001) . This disease  is characterized  by low BMD  and 
fractures. The fractures associated with the greatest morbidity and mortality, as well as  
economic burden to society, together make up the clinically significant and medically relevant group termed major osteoporotic fractures. In the United States (US), there are an estimated 2 million osteoporotic fractures annually ( Litwic, 2014). The number of 
osteoporotic fractures is projected to increase in both men and women by more than 3- fold over the next 50 years as  a result of the aging population ( WHO,  2007).  
Bone remodeling occurs through the action of osteoclasts, which are involved in the resorption of bone followed by the formation of new bone by osteoblasts. In addition to continued use of calcium  and vitamin  D, the current therapeutic approach to  the treatment  
of osteoporosis through inhibition of bone resorption includes agents such as bisphosphonates ( Rosen, 2017), or the monoclonal antibody, denosumab, that inhibits the 
action of osteoclasts by binding to the receptor activator of nuclear factor kappa-B (RANK) ligand. An alternative approach has been to tip the balance between osteoblastic bone formation and osteoclastic resorption through the use of parathyroid hormone receptor  modulation using teriparatide  (rhPTH[1 –34]).  
Until re cently,  teriparatide has  been the only approved  osteoporosis treatment in  which  
the major mode of action is stimulation of bone formation (anabolic) rather than suppression of bone resorption. Teriparatide has delayed and modest effects on increasing BMD  at the total  hip and femoral neck,  and on decreasing BMD at  the distal 1/3 radius. 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  19 of 60  
  
The increase in cortical porosity that can occur may result in maladaptive effects on  
cortical  bone microarchitecture ( Bilezikian, 2007 ). 
The short- term anabolic effects of teriparatide have been demonstrated in  
histomorphometric analyses of a single transiliac  crest  bone biopsy after administration  
of two sets of tetracycline labels (quadru ple labeling) ( Lindsay, 2006). One month of 
treatment stimulated bone formation on cancellous and endocortical surfaces by both 
modeling-based and remodeling-based formation. Likewise, the same technique demonstrated  stimulation  of bone formation  after  3 months of treatment  with teriparatide,  
but inhibition of bone formation in subjects treated with the antiresorptive agent, denosumab ( Dempster, 2016, AVA Osteoporosis Study). In this study, early stimulation 
of bone formation by teriparatide was observed in cancellous, endocortical, intracortical and periosteal envelopes. The stimulation of bone formation was due to an increase in remodeling-based formation (27%), overflow modeling- based formation (9%), and  
modeling- based  formation (6%) (Dempster, 2017).  
The effects of  abaloparatide on bone histomorphometry were recently  reported in a subset 
of subjects in the ACTIVE trial ( Moreira, 2017). Biopsies were obtained at 12 to18 
months (average 15.5 months) from subjects treated with either abaloparatide, teriparatide, or placebo. Few differences were detected among the three treatments, likely  
due to the fact that only cancellous bone was studied, as well as the late timing of the biopsies when the effects  of the anabolic agents  were declining. 
2.3. Quadruple  Label  Technique  
The purpose of this study is to assess the early effects of abaloparatide in postmenopausal women with osteoporosis using tissue-based indices of bone metabolism and to relate these indices to biochemical markers of bone turnover. All four bone envelopes (cancellous, endocortical, intracortical, and periosteal) will be examined in iliac crest  
biopsies after fluorochrome labeling. The quadruple labeling technique has previously been  described by Lindsay ( Lindsay, 2006).  
As noted above, this novel labeling technique has been found to be highly effective in two studies demonstrating the early effects of anabolic therapy with PTH (1-34) on bone formation in subjects with osteoporosis. It has also been used successfully to investigate  
the early  effects  of PTH  (1-84) replacement  in subjects  with hypoparathyroidism 
(Rubin, 2011). Recently, a quadruple label protocol proved to be particularly useful in 
elucidating the mechanism of action of the sclerostin antibody, romosozumab, in the treatment of osteoporosis ( Chavassieux, 2017). In quadruple -labeled biopsies taken at  
two months, the bone formation rate was dramatically increased compared to pretreatment  levels. However,  in biopsies taken  at 12 months with conventional 
double-labeling, bone formation rate was reduced compared to placebo treatment. If the 
quadruple-labeling protocol had not been employed, it would have been difficult to explain  the large increments in bone mineral density, cancellous bone volume, trabecular 
connectivity, and cortical thickness achieved by romosozumab treatment. The principal advantage of the technique is that it allows measurement of dynamic bone formation variables before and after initiation of a drug treatment in a single biopsy. This eliminates the side- to-side variability  in the traditional paired  biopsy study design and, in any case,  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  20 of 60  
  
such a design is not practical to study early effects (within 3 months) of drug 
administration. In  the quadruple labeling  technique, two  different  fluorochromes 
(demeclocycline HCl and tetracycline HCl)  are used for the pre -treatment  and 
on-treatment labels. The difference in color of each fluorochrome allows any label to be 
unambiguously identified as a pre- treatment or on -treatment label, even if only one set of 
labels  is present in a particular  forming  osteon. 
To prepare for biopsy, subjects will be given two sets of fluorochrome labels in the 
following way. The first set of labels will be given to all subjects in standard format: 3 
days of demeclocycline HCl (150 mg, four times per day), a 12-day intermission, and 3 more days of demeclocycline (same dose). After the first set of labels has been  
administered, daily administration of 80 µg abaloparatide will commence. This treatment will be continued during administration of the second set of labels and until the day of biopsy. Approximately 23-26 days before the Month 3 visit, a second set  of double labels  
will be administered following the same schedule, but this time using tetracycline HCl (250 mg, four times daily  for 3 days on, 12 days off, 3 days on). 
Standard transiliac crest bone biopsies will be performed 5 to 8 days after the last day of tetracy cline administration following standard procedures (See Section 7.2.10). The 
biopsies will be embedded in methyl methacrylate and prepared in a standard fashion for histomorphometric analysis. Serial sections from each subject will be examined under UV light for evaluation of tetracycline labels  and under  polarized  light after  staining  with 
toluidine blue for evaluation of reversal and cement lines. 
Using two sets of fluorochrome labels, which differ in their color under fluorescent light 
enables  one to distinguish the first  and second sets  of labels,  even  when only single labels  
are present. Using standard histomorphometry, mineral apposition rate and mineralizing surface can be measu red for the two separate labeling periods, and bone formation rates 
can be calculated. The technique has two key advantages over paired biopsies. First, only one biopsy is required. Second, each subject serves as his or her own pretreatment 
control, elimin ating problems caused by the large intersubject variability in 
histomorphometric variables.  
2.4. Bone  Histomorphometry Results from  Study  BA058 -05-003 
In Study BA058-05-003, a subset of subjects at selected centers was asked to undergo a 
bone biopsy ( Moreira, 2017). Biopsies were obtained after the subjects had received  
between  12 and 18 months of treatment and  were obtained primarily  to assess safety.  
Qualitative histological analysis of biopsies from abaloparatide -treate d subjects revealed  
normal bone microarchitecture without evidence of adverse effects on mineralization or  
on the formation of normal lamellar bone. There were no bone marrow abnormalities or 
marrow fibrosis, nor was there presence of excess osteoid or woven bone. There were 
few significant differences among the three treatment groups in a standard panel of static and dynamic histomorphometric indices. The mineral apposition rate was higher in the teriparatide -treated group than in the placebo-treated group. The eroded surface was  
lower in the abaloparatide-treated group than in the placebo-treated group. Cortical porosity was higher in both the abaloparatide- and the teriparatide-treated groups than in the placebo -treated  group. 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  21 of 60  
  
2.5. Study  Rationale  
The purpose of this study is to assess the early effects of abaloparatide in postmenopausal 
women with osteoporosis using tissue-based indices of bone metabolism obtained by iliac 
crest bone biopsy after quadruple tetracycline labeling and to rel ate these indices to  
biochemical markers of bone turnover. All four bone envelopes (cancellous, endocortical, 
intracortical,  and periosteal) will be examined.  
2.6. Dose  Rationale  
The approved dose of abaloparatide in the US for the treatment  of postmenopausal 
women  at a risk for fracture  is 80 µg per day. 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  22 of 60  
  
 
3. STUDY  OBJECTIVES AND  ENDPOINTS  
3.1. Objectives  
1. Demonstrate the early effects of abaloparatide on tissue-based indices of bone 
formation  and resorption 
2. Assess the degree to which increased bone formation is  achieved by  modeling, 
remodeling, and overflow bone formation  
3. Relate the early indices of tissue -based bone formation and bone resorption to 
those measured using biochemical markers of  bone  turnover 
 
3.2. Endpoints  
• Change from  baseline to 3 months in  dynamic indices  of bone formation  in 
the relevant bone envelopes (cancellous, endocortical, intracortical, and  
periosteal)  
− Mineralizing  surface (MS/BS)  
− Mineral  apposition rate (MAR)  
− Bone formation  rate (BFR/BS)  
• Structural  indices  in the relevant  bone envelopes at Month 3 
− Cortical porosity  (Ct.Po/Ct.Ar) 
• Static  indices in  the relevant bone envelopes at Month 3 
− Osteoid  volume (OV/BV)  
− Osteoid  surface  (OS/BS)  
− Osteoid  thickness (O.Th) 
− Wall  thickness (W.Th) 
− Eroded surface (ES/BS)  
• Change from  baseline to 3 months in special  histomorphometric  variables  in 
the relevant bone envelopes  
− Remodeling, modeling, and overflow modeling- based  formation  
(RmF/BS,  MF/BS,  oMF/BS)  
• Change in serum procollagen type I N-terminal propeptide (s- PINP) and  
carboxy- terminal cross -linking telopeptide of type I collagen (s- CTX) from  
baseline to 1 and 3 months 
• Correlations of tissue -based  indices  of bone formation  and bone resorption  
with s-PINP and s- CTX  
• Overall safety and tolerability of abaloparatide in postmenopausal women 
with osteoporosis. 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  23 of 60  
  
 
4. STUDY  DESIGN  
4.1. Description  of the Study  Design  
This is an open- label, single -arm, multicenter study enrolling approximately 25 
postmenopausal women with osteoporosis at approximately 5 study centers. The study is 
designed to measure the early effects of abaloparatide on tissue-based bone formation and resorption variables based on samples obtained by iliac crest bone biopsy after fluorochrome labeling. The study will consist of a Screening Period (up to 1 month), a Pretreatment Period (approximately 1 month), a Treatment Period (3 months), and a Month 4 visit one month after the last dose of study medication. Biopsies are to be obtained at 3 months of treatment for  the following  reasons:  
• This is the optimal time for changes in  biochemical  markers  of bone turnover 
to predict changes in BMD after 18 months of treatment with abaloparatide 
(Radius, Data on file)  
• Longer periods of time increase the risk that the initial set of labels will be  
resorbed, which would seriously confound the results  
• Comparisons to  the 3- month  results  for teriparatide  from  the AVA 
Osteoporosis Study will be  possible ( Dempster, 2016) 
Figure 1: BA058-05- 020 Study Design, Including Schematic of Bone Biopsy  
Labeling  Procedure  
 

Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  24 of 60  
  
Full details  of the protocol required  assessments can  be found in the Schedule of 
Assessments and Procedures ( Section 7.2.1).  
There will be a sub -study at selected sites to collect pQCT data and extend an additional 
3 months of study drug administration for a  total of 6 months of treatment. 
Details of the schedule of measurements, endpoints and statistical analysis methods for 
the sub-study will be  described in a separate document. 
 
5. SELECTION OF STUDY  POPULATION  
5.1. Inclusion  Criteria  
Subjects  must meet all of  the following criteria  to be eligible  to participate  in this study: 
1. The subject  is a healthy  ambulatory postmenopausal female from  50 to 85 years  
of age (inclusive) with osteoporosis. 
2. The subject  has been  postmenopausal for at least  5 years.  Postmenopausal status 
will be established by a history of amenorrhea for at least 5 years and by an elevated  follicle -stimulating  hormone (FSH) value of ≥ 30 IU/L.  
3. The subject has a BMD T -score ≤ -2.5 at the lumbar spine (L1-L4) or hip 
(femoral neck or total hip) by DXA or lumbar spine or hip BMD T- score ≤ -2.0 
with a history of low trauma vertebral, forearm, humerus, sacral, pelvic, hip, femoral, or tibial fracture sustained within 5 years prior to enrollment. These fractures  must be documented by radiograph or hospital report. 
4. The subject is in good general health as determined by medical history and 
physical ex amination (including vital signs), has a body mass index (BMI) of 18.5 
to 33, inclusive, and is without evidence of clinically significant abnormality in the opinion of the Investigator. 
5. The subject has serum calcium (albumin -corrected), PTH (1 -84), phosphorus, and 
alkaline phosphatase levels all within the normal range during the Screening 
Period. Any subject with an elevated alkaline phosphatase value, and who meets all other entry criteria, is required to have a normal bone- specific alkaline 
phosphatase result to be enrolled. 
6. The subject has serum 25- hydroxyvitamin D values ≥ 20 ng/mL and within the  
normal range. Subjects with serum 25-hydroxyvitamin D levels < 20 ng/ml may 
be treated  with vitamin D3 and re- tested once.  
7. The subject’s resting 12-lead electrocardiogram (ECG) obtained during screening 
shows no clinically  significant abnormality.  
8. The subject  has read,  understood, and signed the written  informed  consent form. 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  25 of 60  
  
5.2. Exclusion  Criteria  
Subjects with  any of the following characteristics are not eligible to participate in the  
study: 
General  exclusion criteria 
1. Presence of abnormalities of the lumbar spine that would prohibit assessment of 
lumbar spine BMD, defined as having at least  2 radiologically  evaluable vertebrae 
within  L1-L4. 
2. Unevaluable hip BMD  or subjects who  have undergone bilateral  hip replacement  
(unilateral  hip replacement is acceptable).  
3. History  of bone disorders (eg, Paget’s  disease)  other  than postmenopausal 
osteoporosis. 
4. Clinically significant abnormality of serum hemoglobin, hematocrit, white blood 
cells (WBC) and platelets, coagulation, or usual serum chemistry: electrolytes, renal  function, liver function and serum proteins. 
5. Unexplained elev ation  of serum alkaline  phosphatase. 
6. History  of radiotherapy (radiation therapy), other than radioiodine. 
7. History of bleeding disorder that would preclude a bone biopsy, in the opinion of the Investigator. 
8. History of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular,  
gastrointestinal, endocrine, central nervous system, hematologic or metabolic 
diseases, or immunologic, emotional and/or psychiatric disturbances to a degree 
that would interfere with the interpretation of study data or c ompromise the safety  
of the subject.  
9. History of Cushing’s disease, hyperthyroidism, hypo- or hyperparathyroidism, or 
malabsorptive syndromes within the past year.  
10. History of significantly impaired renal function (serum creatinine > 177 µmol/L  
or > 2.0 mg/dL). If the serum creatinine is > 1.5 and ≤ 2.0 mg/dL, the calculated  
creatinine clearance (Cockcroft -Gault) must be ≥ 30 mL/min.  
11. History of any cancer within the past 5 years (other than basal cell or squamous cell cancer of the skin). 
12. History of osteosarcoma at any time or a history of hereditary disorders which could predispose the subject to osteosarcoma.  
13. History  of nephrolithiasis or urolithiasis  within the  past five years.  
14. Subjects known to be positive for hepatitis B, hepatitis C, human immun odeficiency virus infection (HIV- 1 or HIV -2). Testing is not required in 
the absence of clinical signs and symptoms suggestive of HIV infection or acute 
or chronic hepatitis.  
Medication -related  exclusion  criteria  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  26 of 60  
  
15. Known history of hypersensit ivity to any of the test materials, related  compounds, 
or tetracyclines.  
16. Prior treatment  with  PTH  or PTHrP  drugs, including abaloparatide.  
17. Prior treatment with IV bisphosphonates at any time or oral bisphosphonates 
within the past three years. Subjects who had received a short course of oral bisphosphonate therapy (3 months or less) may be enrolled as long as the treatment  occurred 6 or more  months prior to  enrollment.  
18. Treatment with fluoride or strontium in the five years prior to the Screening 
Period, or prior treatment with gallium nitrate, or with any unapproved bone- acting  investigational agents at any  time.  
19. Treatment with calcitonin, SERMs (such as raloxifene or tamoxifen), or tibolone, within the 6 months prior to the Screening Period. Estrogens administered as hormone replacement therapy  with or without progestins are not exclusionary. 
20. Treatment  with anticonvulsants that  affect  vitamin  D metabolism (phenobarbital, 
phenytoin, carbamazepine or primidone) or with chronic heparin within the 6 months prior to the Screening  Period. 
21. Prior treatment  with denosumab. 
22. Daily treatment with oral, intranasal or inhaled corticosteroids within the 12  
months prior to the Screening Period. Occasional use of  corticosteroids (for 
seasonal  allergies or asthma)  is not exclusionary. 
23. Prior treatment  with  anabolic steroids or calcineurin  inhibitors (cyclosporin, 
tacrolimus).  
24. Exposure to an investigational drug within the 12 months prior to the Screening Period. 
Lifestyle -related  exclusion  criteria  
25. Abnormal nutritional status (abnormal diets, excessive or unusual vitamin or 
herbal intakes, malabsorption, significant recent weight change), vitamin D intake 
of ≥ 4,000 IU/day  or vitamin  A intake of ≥ 10,000 IU/day. 
26. Subject is known to abuse alcohol or use illegal drugs within 12 months of the Screening  Period. 
 
5.3. Participant  Withdrawal  or Termination  
5.3.1. Reasons for Withdrawal or Termination  
Subjects will be informed that they have the right to withdraw from the study at any time 
for any reason without prejudice to their medical care.  
The Investigator must withdraw subjects from the study for the following reasons: 
• Hypercalcemia as  described  in Section  5.7.1; 
• Severe hypersensitivity to abaloparatide;  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  27 of 60  
 • Refusal  of treatment; 
• Inability  to complete study procedures; 
• Lost to follow-up. 
The Investigator also has the right to withdraw subjects from the study for any  of the 
following reasons:  
• Serious adverse events  (as described  in Section  8.1.2);  
• A complex of adverse events  which, in the judgment of the Investigator, 
justifies  treatment cessation;  
• Serious intercurrent  illness; 
• Non-compliance;  
• Protocol violations; 
• Administrative  reasons.  
Subjects  will be  offered the opportunity to discontinue from the study for the following 
reasons  after site consultation with the  Study Medical Monitor: 
• Incident  vertebral  or nonvertebral fragility  fracture 
Should a subject who experiences a clinical vertebral or nonvertebral fragility fracture  
choose to remain in the study, she will be asked to sign an additional Informed Consent 
Form  further explaining the potential risks and benefits of remaining in the study. 
 
5.3.2. Handling  of Participant  Withdrawals or Terminations  
If a subject is withdrawn or discontinued from the study, the reason for withdrawal from the study is to be recorded in the source documents and on the case report form. All subjects withdrawn prior to completing the study should be encouraged to complete study procedures scheduled for the Month 3/Early Termination visit and to return in one month for a follow-up visit.  The Sponsor Medical  Monitor will decide if the tetracycline  
labeling procedure and bone biopsy will be performed as part of the Early Termination visit. All adverse events should be followed as described in Section 8. Subjects who discontinue or are withdrawn from the study may be replaced.  
 
5.4. Concomitant  Medications  
Vitamin D supplements are required to be administered daily from the Pretreatment 
Period until the end of the Treatment Period. Calcium will also be administered daily,  
with the exception of the days of administration of demeclocycline and tetracycline where calcium administration will be withheld. The doses and schedule of calcium and vitamin D supplements ( Section 7.2.5) should be adhered to and not be changed other 
than for medical necessity. The supplements should be taken in the evening with or 
without food or as otherwise instructed by the Investigator. Calcium (500–1000 mg) and 
vitamin D (400–800 IU) supplements will be sourced locally by the site and provided to the subjects at the  expense of the Sponsor. 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  28 of 60  
  
Two different fluorochromes (demeclocycline HCl and tetracycline HCl) are used for the  
pre-treatment and  on-treatment labels. Instructions  for administration  of fluorochromes is  
detailed  in Section 7.2.6 and Section 7.2.9. 
For any required concomitant medication, such as statins or antihypertensives, the subject 
must be on a stable dose at study entry and every effort should be made to maintain a stable  dose during study participation.  
The occasional use of over-the-counter medications at approved doses (eg, ibuprofen or acetaminophen)  for headache or minor discomfort is allowed.  These are to be recorded on 
the appropriate eCRF. Subjects sh ould not take any other medications, including over- 
the-counter medications, herbal medications, or mega-doses of vitamins during the study 
without prior approval of the Investigator. 
If it becomes necessary  for a subject to take any other  medication during the study, the 
specific medication(s) and indication(s) must be discussed with the Investigator. All 
concomitant medications taken during the course of the study must be recorded in the subject’s  medical  record  or source document and  transcribed into the eCRF.  
 
5.5. Prohibited  Medications  
Please refer to  Section 5.2 for medication -related  exclusion criteria.  
Subjects cannot take any medications, including over-the-counter, non-prescription 
medication, with the exception of those noted in Section 5.4, within 72 hours prior to dosing on Day 1. In addition, subjects are ineligible for the study if they have an abnormal nutritional status (abnormal diets, excessiv e or unusual vitamin or herbal 
intakes,  malabsorption). 
Occasional short -term (≤ 1 week) use of inhaled corticosteroids for seasonal allergies or  
asthma is not prohibited. Subjects who require chronic treatment with either an 
anticonvulsant (phenobarbital, phenytoin, carbamazepine or primidone), or with  heparin  
will be  discontinued. 
 
5.6. Premature Termination  or Suspension  of Study  
This study may be temporarily  suspended or prematurely  terminated if there is sufficient 
reasonable cause. Written notification documenting the reason for study suspension or termination will be provided by the suspending or terminating party to the Principal Investigator (PI), and regulatory authorities. If the study is prematurely terminated or suspended, the PI will promptly inform the Institutional Review Board (IRB) and will provide the reason(s) for the termination or  suspension. 
Circumstances  that may  warrant  termination or  suspension include, but are not limited  to: 
• Determination  of unexpected, significant, or unacceptable risk to participants  
• Insufficient  compliance with  protocol requirements  
• Data that are  not sufficiently  complete and/or evaluable 
• Decision  of Sponsor 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  29 of 60  
  
The study may resume once concerns about safety,  protocol compliance, or data quality  
are addressed and  satisfy  the Sponsor, IRB, and/or Regulatory Agencies,  if applicable.  
 
5.7. Temporary  Suspension  of Treatment 
The Investigator has the right to suspend treatment with study medication for up to 7 
cumulative days, without withdrawal of the subject from the study. Reasons for 
temporary  suspension of treatment may  include a medical  reason unrelated  to an  adverse 
event (eg, a planned procedure), or important social or administrative events. The reason for the suspension of treatment is to be documented in the eCRF and in source documents. 
When treatment is restarted, the subject should resume treatment with the next scheduled  
dose and continue until the scheduled End-of- Treatment.  
Subjects  who develop hypercalcemia during the study are to have treatment with  calcium  
and vitamin D temporarily  suspended as described below. 
 
5.7.1. Treatment  Algorithm in Subjects  Who Develop  Hypercalcemia  
For any predose serum calcium (albumin -corrected) value which is ≥ 0.3 to 1.0 mg/dL, 
corresponding to ≥ 0.08 to 0.25 mmol/L, above the upper limit of normal (ULN)  
(inclusive), the Investigator will confirm hypercalcemia by drawing a new serum sample 
as soon as possible a fter the  result is received.  
If a subject’s predose serum calcium is elevated on repeated testing, calcium and vitamin  
D supplementation should be withheld. If the subject’s serum calcium remains elevated 1 to 2 weeks after calcium and vitamin D supplementation is withheld, dosing of study medication should be stopped. Treatment can be restarted if other causes of 
hypercalcemia are excluded after consultation with the Sponsor. Treatment with study 
medication  should not be suspended for greater than 7 days. 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  30 of 60  
  
 
6. STUDY  DRUG  ADMINISTRATION  AND  MANAGEMENT 
6.1. Study  Medication  
6.1.1. Abaloparatide 
Abaloparatide injection is supplied as a sterile, colorless, clear solution in a glass 
cartridge which is pre-assembled into a disposable single- subject -use pen. The pen is 
intended to deliver 30 once daily  abaloparatide doses of 80 µg in 40 µL of solution. Each 
pen contains 3120 mcg/1.56 mL. 
Additional information  will be provided to  clinical  sites in  a separate Pharmacy  Manual  
including instructions on how to use the injection pen. 
 
6.2. Packaging,  Labeling  and Storage 
6.2.1. Packaging and Labeling  
Abaloparatide will be supplied and packaged  as injection  pens. All  packaging  operations 
will be performed  in accordance with Good Manufacturing Practices (GMP).  
All Investigational Product (IP) will be supplied to study sites packaged and labeled 
according to local regulations with a statement that all IP is limited to investigational use  
only. A detailed study drug dispensation plan will be provided in the Pharmacy  Manual.  
 
6.2.2. Storage 
While  at the clinical  site,  abaloparatide injection  pens must be stored  in a secure,  limited  
access, temperature monitored refrigerator at 2°C to 8°C (36°F to 46°F) until dispensed 
for use to a study subject  or until returned to the Sponsor. 
After  the abaloparatide injection pen is used for the first time,  the pen may  be stored  for 
30 days at room temperature, 20°C to 25°C (68°F to 77°F). Unused pens should be refrigerated until use. Instructions regarding the storage and handling of the study drug 
after dispensation to subjects will be  provided to sites in the Pharmacy  manual.  
6.3. Treatment Assignment  
All subjects who sign informed consent for the study will be assigned a unique 6-digit 
subject number which will be used to identify subjects throughout the study and on the eCRFs.  Subject numbers will be  assigned  as follows:  
XXX YYY,  where:  
• XXX represents  the study site number; 
• YYY represents  the subject  ID number 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  31 of 60  
  
6.4. Dosing and Administration  
Subjects will self -administer a single daily dose of 80 µg of study medication 
(abaloparatide)  during the Treatment Period.  
The first self-administration is  to occur at  the study  site under observation. On the days of 
clinic visits, study medication must be administered in the clinic to accommodate  
procedures. Study personnel may  administer the  study medication  during clinic visits.  
Subjects will be trained by study personnel during the Pretreatment Period how to 
self-inject study medicatio n with the abaloparatide injection pen. If a subject requires 
assistance with study medication administration, an individual (eg, a family member)  
who has been trained by  study personnel may provide assistance.  
Subjects will also be provided written instru ctions on how to use the abaloparatide 
injection pen. Subjects will be instructed by the study site to inspect the contents of their 
injection pen before each injection. If the cartridge contents are not clear and colorless, or if the contents contain particles, the subjects will be instructed not to use the pen and to contact the study site for further guidance. Injections should be administered at the same time each day. If a dose is missed, the dose should be administered as soon as possible up 
to 12 hours  after the missed  injection.  Any time thereafter,  the dose should be skipped 
and the drug should be administered at the next scheduled time the following day. All  
injections are to be given in the periumbilical region of the abdomen, rotating the site of  
injection each day, and administered at approximately the same time every day. If it is deemed medically necessary by the Investigator for an injection to be administered at a site other than the abdomen, the alternate site of injection is to be re corded and the reason 
for the change documented in the medical chart and eCRF as a protocol deviation. On the first day of study medication administration, the subject should self- inject while in a  
sitting or lying position at the study site and remain in that position for approximately 5 minutes. The subject is to remain under observation for a minimum of 60 minutes after the initial injection. A blood pressure measurement will be taken 60 minutes after the 
injection. Subjects are to be instructed to self-inject at home in a location where they have 
the ability  to sit or lie  down. 
Subjects will be instructed to use a new pen after each 30 -day period. At each clinic visit 
during the Treatment  Period, the used  abaloparatide injection  pens should be returned. 
Compliance,  adverse events,  and use of concomitant medications  should be reviewed  
upon drug re-supply and documented accordingly in the drug accountability log and 
eCRF.  
 
6.5. Treatment Compliance  
To ensure treatment  compliance,  the Investigator or designee will supervise all study 
drug administration that occurs  at the site.  At each study visit,  the Investigator or 
designee will review subject compliance with study drug administration and remind the 
subject of study drug dosing requirements. Subject compliance will be ascertained by two 
methods: subject diaries  and measuring residual drug in the cartridge.  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  32 of 60  
  
Discrepancies  between  expected  and actual  dosing will be  assessed  and discussed with  
the subject. All discrepancies, causes and subject retraining will be documented in the 
medical charts, and recorded in the eCRF as appropriate. If a subject does not take all  
study medication (abaloparatide) as required, the reason for the missed dose is to be 
discussed  with the  subject  during the visit.  
Although calcium and vitamin D are considered concomitant medications for this study, 
missed doses of calcium and vitamin D will be determined by performing a pill count. If 
a subject demonstrates continued noncompliance with required abaloparatide dosing 
despite educational efforts, the Investigator should contact the Sponsor Medical Monitor to discuss discontinuation of the subject from the Study. 
6.6. Study  Drug  Accountability  
The Investigator or designated  site staff will maintain  records  documenting the dates  and 
amounts of the following: 
• Study drug received  
• Study drug dispensed to the subjects  
• Study drug returned by the subjects  
• Study drug returned to RADIUS/designee or destruction of study drug on site 
Subjects  will be  instructed to  return all used and unused study drug to the site.  The study 
drug will be retained at the site until inventoried by the study monitor and approved for destruction or return. The study monitor will verify study drug records and inventory throughout the study. 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Stud y BA058 -05-020, Amendment  2 Page  33 of 60  
  
 
7. STUDY  PROCEDURES  AND  SCHEDULE  
7.1. Study  Procedures  
The study- specific assessments are detailed in this section and outlined in Table 1 . Any 
results  falling  outside of the reference ranges  may  be repeated  one time at the discretion  
of the Investigator. 
 
7.2. Study  Schedule  
This st udy is comprised of six clinic visits. Study assessments are to be performed 
according  to the Schedule of Events ( Table 1). There  is a ± 4 -day window for each clinic  
visit, other than the Day 1 for which there is a +4 -day window and Month 4 visit for 
which there is a ± 7 -day window. 
The study will consist of a Screening  Period (up to 1  month), a Pretreatment  Period  
(approximately 1 month), a Treatment Period (3  months), and a Month 4 Visit 
(one month). During the Tre atment Period, subjects will have clinic visits for study - 
related protocol procedures at Day 1, Month 1, and Month 3. For the purpose of this 
study, one month is equal to 30 days. 
 
7.2.1. Schedule  of Assessments and Procedures  
A comprehensive Schedule of Assessments and  Procedures is  presented  in Table 1. 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  34 of 60  
  
 
 
 
Table 1: Schedule  of Assessments and Procedures  
 
 
 
 
Procedure  Visit  1 Visit  2 
(±4 days)  Visit  3 
(+4 days) Visit  4 
(±4 days)  Visit  5 
(±4 days)  Visit  6 
(±7 days)  
Screening  
(30 Days)  Pre- 
treatment  Day 1 Month 1  Month 3  Month 4  
Informed  consent  X      
Verification  of entry  criteria  X X     
Review  of medical historya
 X X X X X X 
Physical  examinationb
 X      
Symptom  directed  physical  examination   X X X X X 
Vital signsc
 X X X X X X 
Weight  and height  measurementsd
 X  X X X X 
12-lead Electrocardiograme
 X  X  X X 
Urinalysis  (dipstick)f
 X  X X X  
Chemistry  blood  collectiong
 X  X X X  
Hematology  blood  collection  X  X X X  
Coagulation  (PT and PTT)  blood  collection  X    X  
PTH  (1-84) X    X  
25-hydroxyvitamin  D level  X      
1,25-dihydroxy  vitamin  D level  X      
FSH X      
Thyroid  stimulating  hormone  X      
Injection  training  for subjects   X     
Dispense  calcium  and vitamin  D supplementsn X X X X   
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  35 of 60  
  
 
 
 
 
Procedure  Visit  1 Visit  2 
(±4 days)  Visit  3 
(+4 days) Visit  4 
(±4 days)  Visit  5 
(±4 days)  Visit  6 
(±7 days)  
Screening  
(30 Days)  Pre- 
treatment  Day 1 Month 1  Month 3  Month 4  
Study  medication  (abaloparatide)  administration    Daily  abaloparatide administration  until 
and including the day  of bone  biopsy   
Demeclocycline (dispense  and administration)   Xh     
Tetracycline (dispense and administration)     Xi   
Transiliac  crest bone  biopsyj
     X  
Serum  markers  of bone  metabolism  (PINP  and 
CTX)    X X X  
AP and lateral lumbar  and thoracic  spine  
radiographs  X      
Clinical  assessment of  new fracturesk
  X X X X X 
Collect blood  for immunogenicity  testing    X  X  
BMD  of lumbar spine,  total hip, and  femoral  
neck  X    X  
Investigator  assessment of  local  tolerance  
(dermal  reactions  assessment)    X X X  
Subject diary  reviewl
   X X X  
Document  AEs and concomitant medicationsm
 At any  time,  question subject at each  visit 
Drug  supply/resupply/accountability   X X X X  
a Including alcohol  and tobacco  use assessment.  
b A complete physical examination includes a review of the following systems: head/neck/thyroid, eyes/ears/nose/throat, respiratory, cardiovascular, lymph 
nodes, abdomen, skin, musculoskeletal, and neurological. Breast, anorectal, and genital examinations will be performed when medically indicated. After  
screening, any clinically  significant abnormal  findings  in physical examinations  not present  at screening  should be  reported  as AEs.  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  36 of 60  
  
 
c Vital signs include blood pressure (systolic and diastolic), temperature (oral), pulse rate, and respiratory rate. These will be assessed following a 5- minute rest 
(seated or supine) and before blood sample collection. At visits when study drug is administered at the site, vital sign asse ssments will be collected before the 
dose of study drug. Only blood pressure, pulse rate, and respiration rate are to be recorded one hour post -dose. Supine and standing blood pressure  
measurements  will be performed  at each  visit during the Treatment  Period.  
d Height  is to be  measured in  the standing position  with shoes off using  a medical  stadiometer.  
e An ECG  will be recorded  immediately  prior  to dosing and one hour post-dose during the Treatment  Period.  
f All routine urinalysis will be performed on a sample freshly voided during the visit and sent to a central lab for microscopy if test is positive for micro- 
organisms  via dipstick.  
g Serum  chemistry  will be measured predose  at Visits  3, 4, and 5. 
h Eighteen days before Day 1 of the Treatment Period (Visit 3), subjects who remain eligible for study participation will begin the first bone biopsy labeling 
procedure  with administration  of 150 mg demeclocycline  4 times  daily  for 3 days followed by a 12-day intermission,  and then demeclocycline for 3 additional 
days at the  same dose.  
i Approximately 23 to  26 days  before  Month 3 (Visit 5), subjects  will begin the second bone  biopsy labeling  procedure  with administration  of 250 mg 
tetracycline  4 times  daily  for 3 days  followed  by a 12-day intermission,  and then tetracycline  for 3 additional  days at the same  dose.  
j Transiliac  crest  bone  biopsy 5- 8 days  after last  tetracycline  dose. Sponsor  Medical  Monitor  will decide if included in  Early  Termination  Visit.  
k If the subject reports that a fracture has occurred, remind the subject to bring X -rays and any medical reports of the fracture to the next clinic visit.  
Documentation  must  be obtained  on all new fractures  that occur  during the study.  This documentation should  be maintained  in the source documents.  
l. Subject will be instructed on completion of diary in the Pretreatment Period to include administration of medications for bone biopsy labeling procedure. The  
subject  medication  diary  will be reviewed by  study personnel  at each study  visit during the Treatment  Period to ensure  subject  compliance.  
m AEs and SAEs  will be recorded  on the case report  forms  starting  from  the time of subject entry  into the Screening  Period (Visit 1) of the study  (signed  
informed  consent)  until 30 days  after the last dose of study  medication. All AEs  will be followed until resolution  or stabilization. Any  SAEs  that occur  at any 
time after completion  of the study,  which  are considered by the Investigator  to be  related to  study treatment,  must  be reported to the  Sponsor  or its designee.  
n Vitamin D supplements are required to be administered daily from the Pretreatment Period until the end of the Treatment Period. Calcium will also be  
administered  daily, with  the exception of the days of administration  of demeclocycline and tetracycline  where  calcium  administration  will be withheld.  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  37 of 60  
  
7.2.2. Informed  Consent  Process  
Each subject must sign and date a study-specific informed consent form (ICF) before any 
study specific procedures can be performed. The consent forms will comply with all applicable regulations governing the protection of human subjects. An ICF, approved by RADIUS and the site's institutional review board (IRB) must be used. The Investigator or designee must record  the date when  the ICF was signed in the subject’s  source document. 
7.2.3. Assigning  Subject  Numbers  
Once a subject has  signed an  ICF, a subject  number will be  assigned. The  subject will 
retain  this number for the entire study. 
 
7.2.4. Subject  and Disease  Characteristics  
Subject  and disease characteristics  include the following: demographics, medical  history, 
height, and  weight. 
Medical history will be elicited from each subject during screening. Based on the medical history, the subject will be assessed for any disqualifying medical conditions as specified 
in the inclusion and exclusion criteria. The medical history shall include a complete 
review  of systems, past  medical and surgical histories,  and any allergies.  
Subjects  included into the study based  on a history of low-trauma nonvertebral fractures  
must have sufficient source documentation in the form of a medical report or 
radiographic films as evidence of such history. 
 
7.2.5. Screening  (Visit  1) 
Signed informed consent will be obtained and eligibility for study entry assessed. Subjects  who  are eligible for  the study on the basis  of screening  evaluations  will enter  the 
Pretreatment Period of the study and will be provided calcium and vitamin D supplements. This should be continued through the Treatment Period according to the subject’s  need, so that they have an intake of at least 1200 mg/day of calcium and  
800-1000 IU/day  of vitamin  D. Vitamin D  supplements are required  to be administered  
daily from the Pretreatment Period until the end of the Treatment Period. Calcium will 
also be administered daily, with the exception of the days of administration of 
demeclocycline and tetracycline, where calcium administration will be withheld. The  
following baseline screening  evaluations will be performed: 
• Obtain Informed Consent 
• Verification  of study entry  criteria  
• Review  of medical  history 
• Physical  examination  
• Blood pressure  and vital signs (see  Section 7.3) 
• Weight  and height (see Section  7.3) 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  38 of 60  
 • 12-lead ECG  
• Laboratory testing  of serum  chemistry,  hematology, urine dipstick, and 
coagulation 
• PTH,  25-hydroxyvitamin D,  and 1,25-dihydroxyvitamin D levels  
• FSH and TSH  levels  
• Lumbar and  thoracic spine radiographs (anteroposterior and lateral)  
• BMD assessments of lumbar spine, total hip and femoral neck by dual X- ray 
absorptiometry (DXA)  
• AE and concomitant medication  review  from  signing of the informed consent  
Subjects whose laboratory tests do not fall within the specified ranges as detailed in the 
inclusion/exclusion criteria may have the samples redrawn and the tests repeated within  
30 days of the original test date. If upon reanalysis, the values fall within the inclusion/exclusion criteria,  the subject  may enter  the study. Subjects  who do not meet  
the 25-hydroxyvitamin D entry criterion may receive vitamin D supplementation and be 
retested one time. Similarly, subjects with minor elevations of PTH may be retested one  
time after vitamin D supplementation. All subjects enrolled following retesting must ha ve 
safety  laboratory  results reported within 30 days prior to enrollment. 
All AEs,  including serious  adverse events  (SAEs), will  be recorded from  the time  of 
signing of the informed consent and through the 30 days after the last dose of study 
medication.  
 
7.2.6. Pretreatment  (Visit  2) 
All subjects  will receive calcium  and vitamin  D until the end of the Treatment  Period, 
according to the subject’s need so that they have an intake of at least 1200 mg/day of calcium and 800-1000 IU/day of vitamin D. Subjects should be on a stable dose of calcium  and vitamin D for 30 days prior to initiating  the double labeling  procedure. 
Subjects will undergo training for medication self-administration and for completion of 
diary, to include administration of  medications for  bone biopsy labeling  procedure. 
Vitamin D supplements are required to be administered daily from the Pretreatment Period  until the end of the Treatment  Period. Calcium  will also be administered  daily, 
with the exception of the days of administration of demeclocycline and tetracycline where calcium administration will be withheld. The following procedures will be  
performed:  
• Verification  of study entry  criteria  
• Review  of medical  history 
• Symptom directed physical  exam (see Section  7.3) 
• Blood pressure  and vital signs (see  Section 7.3) 
• Clinical assessment  of new  fractures  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  39 of 60  
 • AE and concomitant medication  review  
• Dispense demeclocycline,  vitamin  D and  calcium  
• Drug  accountability  
• Subject  injection  training  
Eighteen  (18) days before Day  1 of the Treatment  Period  (Visit 3),  subjects  who remain  
eligible for study participation will begin the first bone biopsy labeling procedure with 
administration of 150 mg demeclocycline 4 times daily for 3 days followed by a 12- day 
intermission,  and then demeclocycline for 3  additional days at the  same dose.  
Demeclocycline should be taken  on an  empty  stomach, at  least  1 hour before meals  and 2 
hours after  a meal with a  full glass of water.  
 
7.2.7. Treatment  Period  
At each  clinic  visit during the Treatment  Period, recent  health status  will be  obtained, the 
diary reviewed, adverse events and concomitant medications collected, drug supply / 
resupply and accountability, and blood pressure and vital signs performed. Laboratory assessments of serum chemistry, hematology and urinalyses will be obtained at Day 1, Month 1, and Month 3. Clinical assessments for fracture will be performed at each visit. Source documentation (imaging report and/or film along with other supporting documentation as appropriate) will be collected from each site to confirm fracture. If the subject reports that a fracture has occurred, remind the subject to bring X-rays and any medical reports of the fracture to the next clinic visit. Documentation must be obtained on all new fractures that occur during the study. This documentation should be 
maintained  in the source documents. 
Bone turnover marker assessments (s -PINP and s- CTX) will be performed on the Day 1, 
Month 1 and Month 3 visits (Visits 3, 4, and 5, respectively). 
 
7.2.8. Day 1 (Visit  3) 
• Review  of medical history  
• Symptom directed  physical exam  (see Section  7.3) 
• Blood pressure  and vital signs (see  Section 7.3) 
• Weight  and height measurement (see Section  7.3) 
• 12-lead ECG  
• Laboratory testing of serum chemistry (predose), hematology, and urine 
dipstick  
• Bone turnover markers  (s-PINP  and s-CTX)  
• Clinical assessments of new  fractures  
• Collect  blood for immunogenicity testing  
• Subject  diary  review  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  40 of 60  
 • AE and concomitant medication  review  
• Dispense abaloparatide,  vitamin  D and  calcium  
• First dose of abaloparatide will be  administered  by the subject in  clinic  
• Investigator assessment  of local  tolerance after  injection  
• Drug  accountability  
7.2.9. Month  1 (Visit  4) 
• Review  of medical  history 
• Symptom directed  physical exam  (see Section  7.3) 
• Blood pressure  and vital signs (see Section 7.3) 
• Weight  and height measurements (see Section  7.3) 
• Laboratory testing of serum chemistry (predose), hematology, and urine 
dipstick  
• Bone turnover markers  (s-PINP  and s-CTX)  
• Clinical assessment  of new  fractures  
• Review  subject  diary  
• AE and concomitant medication  review  
• Dispense abaloparatide,  vitamin  D and  calcium  
• Self-administration  of study medication  when  directed  by site staff after 
completion  of predose activities  
• Investigator assessment  of local  tolerance after  injection  
• Drug  accountability  
Approximately twenty- three (23) to twenty -six (26) days prior to Visit 5, subjects 
will begin the second bone biopsy labeling procedure with administration of 250 
mg tetracycline 4 times daily for 3 days followed by a 12-day intermission, and then tetracycline for 3 additional days at the same dose. Tetracycline should be taken on an empty stomach, at least 1 hour before meals and 2 hours after a meal  
with a full glass of water.  
7.2.10. Month  3/Early Termination (Visit  5) 
• Review  of medical  history 
• Symptom directed  physical exam  (see Section  7.3) 
• Blood pressure  and vital signs (see  Section 7.3) 
• Weight  
 and height measurements  (see Section  7.3) 
• 12-lead ECG  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  41 of 60  
 • Laboratory testing of serum chemistry (predose), hematology, and urine 
dipstick  
• Coagulation blood testing  
• PTH  level  
• Bone turnover markers  (s-PINP  and s-CTX)  
• Clinical assessment  of new  fractures  
• Collect  blood for immunogenicity testing  
• Review  subject  diary  
• AE and concomitant medication  review  
• Self-administration  of last dose of study medication when directed by  site 
staff after completion of predose activities  
• Investigator assessment  of local  tolerance after  injection  
• BMD assessments of lumbar spine, total hip and femoral neck by dual X- ray 
absorptiometry (DXA)  
• Transiliac crest bone bi opsy 5-8 days after last tetracycline dose (Sponsor 
together with the Medical Monitor should determine if included in Early 
Termination  Visit)  
• Drug  accountability  
7.2.11. Month  4 (Visit  6) 
• Review  of medical  history 
• Symptom directed  physical examination  (see Section  7.3) 
• Blood pressure  and vital signs (see Section 7.3) 
• Weight  and height measurements  (see Section  7.3) 
• 12-lead ECG  
• Clinical assessment  of new  fractures  
• All AEs and concomitant medications  review  
7.2.12. Unscheduled Visit  
If the subject returns to the clinic for an unscheduled visit (eg, to follow-up on an abnormal laboratory test),  the procedures performed at  this visit will  be recorded  in the 
eCRF  and source documentation. 
 
7.3. Vital Signs  and Physical  Examinations 
A complete  physical examination  (review  of all  body systems),  height, weight, and  vital 
signs assessment will be  performed  at Screening.  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  42 of 60  
 A complete physical examination includes a review of the following systems: 
head/neck/thyroid, eyes/ears/nose/throat, respiratory, cardiovascular, lymph nodes, abdomen, skin, musculoskeletal, and neurological. Breast, anorectal, and genital examinations will be performed  when  medically  indicated.  After  screening, any clinically  
significant abnormal findings in physical examinations should be reported  as AEs.  
Height and weight will be  measured  with  shoes off. Height is  to be measured  using a wall 
mounted stadiometer.  
Vital signs include blood pressure (systolic and diastolic), temperature (oral), pulse rate, 
and respiratory rate. These will be assessed following a 5 -minute rest (seated or supine) 
and before  blood sample collection. At visits  when study drug is administered  at the  site, 
vital sign assessments will be collected before the dose of study drug. Only blood pressure, pulse rate, and respiration rate are to be recorded one hour post-dose. Supine and standing blood pressure measurements will be performed at each visit during the Treatment Period. After screening, any clinically significant abnormal findings in vital signs should be reported  as AEs.  
 
7.4. 12-Lead  Electrocardiogram  
A standard, 12-lead ECG will be performed. A hard copy of the ECG should be printed 
and signed by the Investigator at  the site. Any abnormalities should be noted, and clinical  
relevance should be documented. An ECG will be recorded immediately prior to dosing 
and one hour post-dose during the Treatment Period. After scre ening, any clinically 
significant abnormal findings in ECGs should be reported as AEs.  
7.5. Laboratory Evaluations  
7.5.1. Clinical Laboratory Evaluations 
Hematology, serum chemistry, and urinalysis will be collected at time points indicated in  
the Schedule of Assessments and Procedures in Table 1 . All clinical laboratory blood 
samples will be sent to a central laboratory for analysis and testing. A list of study  
clinical  laboratory tests is in  Table 2. 
• Subjects whose laboratory tests do not fall within the specified ranges as detailed 
in the inclusion/exclusion criteria may have the samples redrawn and the tests repeated  within  30 days of the original test  date. If  upon reanalysis,  the values fall  
within  the inclusion/exclusion criteria, the subject may  enter  the study. 
 
• Subjects  who  do not meet  the vitamin  D entry  criterion (their  25-hydroxyvitamin 
D is less than 20 ng/ml) may receive vitamin D supplementation and be retested as may subjects with minor elevations of PTH. All subjects enrolled following retesting  must have safety  labs within 30 days of randomization (Day 1). 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  43 of 60  
  
 
Table 2: Clinical Laboratory Tests  
 
Hematology  Serum  Chemistry  Urinalysis  
(dipstick)  a Additional  Tests  
Hemoglobin  
Hematocrit  Sodium  
Potassium  pH 
Glucose  PTH  (1–84)b 
25-hydroxyvitamin Dc 
1,25-dihydroxy  vitamin  Dc 
WBC count with  
differential in absolute  
counts  
RBC count  
Mean  corpuscular  volume  
(MCV)  Chloride  
 
 
Inorganic phosphorus  
Albumin  Protein  
 
 
Ketones  
Bilirubin  Coagulationb 
FSHc 
TSHc 
Mean corpuscular  
hemoglobin  
concentration (MCHC)  Total  protein  Blood   
Mean corpuscular  
hemoglobin  (MCH)  Glucose  Urobilinogen   
Platelet  count  Blood urea  nitrogen (BUN)  Specific  gravity   
 Creatinine  Nitrite   
 Uric acid Leukocytes   
 Aspartate  aminotransferase  (AST)    
 Alanine  aminotransferase  (ALT)    
 Gamma -glutamyltranspeptidase  
(GGT)    
 Creatine  phosphokinase  (CPK)    
 Alkaline  phosphatase    
 Total  bilirubin    
 Lactate  dehydrogenase  (LDH)    
 Total  Cholesterol    
 Triglycerides    
 Total  calcium    
a Local laboratory, send to  a central  lab for  microscopy  if test is positive  for micro -organisms  
b Only  required  at Screening  and Visit  5 (Month  3/Early  Termination)  
c Only  required  at Screening  
In the event of medically significant, unexplained, or abnormal clinical laboratory test 
values, the test(s) should be repeated and followed up until the results have returned to 
within the normal ra nge or an adequate explanation for the abnormality is found. After 
screening,  clinically  significant changes  in laboratory tests that occur  during the course of 
the study are to be reported as adverse events.  
The clinical laboratory will clearly mark all laboratory test values that are outside the 
normal range and the Investigator will indicate the clinical relevance of these out of range values.  
 
7.5.2. Serum  Markers  of Bone Metabolism 
Blood samples will be taken to measure efficacy related markers of bone metabolism at 
Day 1, Month 1, and Month 3 or early termination. Serum procollagen type I N- terminal 
propeptide (s- PINP) and serum carboxy- terminal cross -linking telopeptide of type I 
collagen  (s-CTX) will be  measured in all  subjects.  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  44 of 60  
 7.5.3. Specimen  Preparation,  Handling  and Storage 
The procedures  for the collection,  handling, and  shipping of clinical  laboratory samples  
are specified in a separate Laboratory  Manual provided to each  clinical site.  
 
7.6. Bone  Biopsy  Processing  Procedure 
The bone cores will be processed without decalcification and embedded in methyl 
methacrylate.  Three levels  of transverse  sections from each biopsy block will be cut  100 
micron apart using a Leica SM 2500E Polycut microtome. In each level, two adjacent sections at 7 -micro ns and one adjacent 20-micron thick sections will be collected. The 
two 7 -micron adjacent sections will be stained with toluidine -blue (ethanol base) and 
Goldner’s trichrome, respectively. The toluidine-blue stained section will be used to demonstrate bone cells, osteons, and cement lines. The trichrome stained section will be used to demonstrate osteoid. The 20- micron section will be left unstained for  
visualization of tetracycline labels. Each section will be subjected to histomorphometric  
analysis using computerized image analysis as previously described ( Dempster, 2001;  
Dempster 2017). All variables will be calculated and expressed according to the guidelines of the ASBMR’s  Bone Histomorphom etry Committee  (Dempster, 2013).  
7.7. Imaging Procedures  
All imaging measurements (spine radiographs and BMD by DXA) will be performed according  to the procedures outlined in  the Imaging  Charter  and Imaging Manuals  which  
will be provided as a separate document.  
 
7.7.1. Dual  Energy  X-ray Absorptiometry  (DXA)  
All subjects  will have areal  bone density (aBMD)  measurements  taken  via DXA of the 
lumbar spine, total hip, femoral neck, at Screening (Visit 1). Lumbar spine scans must  
include L1 through L4. Hip scans will include the entire proximal femur to about 2 cm 
below the lesser  trochanter.  
 
7.7.2. Clinical and Radiologic Evaluation of Fractures  
All spine radiographs will be performed according to the procedures outlined in the 
Imaging Charter and Imaging Manual which will be provided as separate documents. All subjects will have X -rays taken to document fractures of the lumbar and thoracic 
vertebrae at Screening to confirm entry criteria. Radiographs of the lateral thoracic and lumbar spine will include coverage of T3 to S1. The lateral spine radiographs will be assessed for prevalent vertebral fractures using the Genant Semi -quantitative (SQ) 
Scoring method ( Genant,  1993).  
• Grade 0: Normal  (approximately  < 20% reduction in  anterior,  middle,  or 
posterior height) 
• Grade 1: Mild  fracture (approximately  20%–25% reduction in anterior,  
middle, or posterior height) 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  45 of 60  
 • Grade 2: Moderate fracture (approximately 25%–40% reduction in anterior, 
middle,  or posterior height) 
• Grade 3: Severe fracture (> 40% reduction in anterior, middle, or posterior 
height). 
Subjects will be clinically evaluated for vertebral and nonvertebral fractures (wrist, hip, 
rib, etc.) which occur during the study. Should a clinical fracture occur, X- ray images and  
reports associated with the fracture must be obtained and maintained in the subject’s medical  record.  
All fractures  will be  identified  and evaluated  as part  of the disease assessment  and will be 
documented in the eCRFs  and source documents. 
 
7.7.3. Treatment  and Imaging at Selected  Sites  
Selected sites will follow expanded treatment and imaging procedures. Sites following 
expanded procedures will be provided instructions and details in a separate document for the sub-study. 
Additional treatment  and imaging procedures at  selected  sites  includes: 
• Abaloparatide treatment  for total of 6 months 
• pQCT  of the forearm and tibiae performed at the pretreatment visit (Visit 2),  
at Month 3 (Visit 5), and at Month 6 (Visit 7).  
 
7.8. Discontinuation  from  the Study  
Subjects may  voluntarily discontinue from the study for any  reason at  any time.  
Subjects  sustaining a radiologically  confirmed incident vertebral  fracture will be  
informed of the finding and will be counseled as to treatment options and may 
discontinue or choose to  remain on the study. 
Subjects  who decide they  do not wish to participate  in the study further should return  for 
the assessments indicated for the Month 3/Early Termination and 30 days later for the 
Month 4 Visit in the Schedule of Assessments and Procedures ( Table 1 ). If they fail to  
return for these assessme nts for unknown reasons, every effort (eg, by telephone, email, 
and letter for a minimum of three attempts) should be made and documented in the subject’s  study file. 
 
7.8.1. Withdrawal of Consent  
Subjects  may  voluntarily withdraw consent to participate  in the study for any reason  at 
any time.  
Withdrawal of consent occurs only when a subject does not want to participate in the 
study anymore and does not want any further visits or assessments and does not want any further study related contact.  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  46 of 60  
 If a subject  withdraws  consent,  the Investigator  must make every  effort  to determine  the 
primary reason for this decision and record this information. Further attempts to contact  
the subject are not allowed unless safety findings req uire communicating  or follow-up. 
 
7.8.2. Early  Study  Termination  
The study can be terminated at any time for any reason by the Sponsor. Should this be 
necessary, subjects should be seen as soon as possible and treated as a prematurely withdrawn subject. The Investigator may be informed of additional procedures to be followed in  order to  ensure that adequate consideration is  given to the protection of the 
subject’s  interests.  
The Investigator will be responsible for informing IRBs  of the early  termination  of the 
study. 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  47 of 60  
  
8. ADVERSE EVENT AND SERIOUS ADVERSE EVENT  
DOCUMENTATION  
8.1. Evaluation  of Safety  
Timely,  accurate,  and complete reporting and analysis of safety  information  from  clinical  
studies are crucial for the protection of subjects and is mandated by Regulatory Agencies 
worldwide. All clinical studies sponsored by RADIUS will be conducted in accordance with Standard Operating Procedures (SOPs) that have been established to conform to regulatory requirements  worldwide to ensure appropriate reporting of safety  information. 
All AEs are collected from the time of the informed consent until 30 days after last dose  
of investigational product. Where possible, a diagnosis rather than a list of symptoms should be recorded.  All AEs should be captured  on the appropriate AE pages  in the eCRF  
and in source documents. The Investigator will assess all AEs and determine reporting requirements  to the Sponsor as well as the IRB.  
8.1.1. Adverse Events  
An AE is any untoward medical occurrence in a clinical investigation subject 
administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or dis ease temporally  
associated  with  the use of a medicinal  (investigational) product, whether or not related  to 
the medicinal (investigational) product ( ICH,  1995).  
AEs include: 
Worsening (change in nature, severity,  or frequency) of conditions present  at the onset of 
the study 
• Intercurrent illnesses  
• Drug  interactions  
• Events related to  or possibly related to concomitant  medications  
• Abnormal laboratory values (this includes significant shifts from Baseline within the range of normal that the Investigator considers to be clinically  
important)  
• Clinically  significant abnormalities  in physical examination, vital signs, and  
weight 
An abnormal laboratory value will not be assessed as an AE unless it requires a 
therapeutic intervention or is considered  by the Investigator to  be clinically  significant.  
 
8.1.2. Serious  Adverse Events  
A serious adverse event (SAE) is any  AE that results in any  of the following: 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  48 of 60  
 • Death  
• Life-threatening: The term “life -threatening” in the definition of “serious” 
refers to an event/reaction in which the subject was at risk of death at the time  
of the event/reaction; it does not refer to an event/reaction which 
hypothetically might have caused death if it were more severe  
• Required  inpatient hospitalization  or prolongation of existing  hospitalization  
• A persistent or significant disability/incapacity (ie, substantial disruption of  
the ability  to conduct normal life function) 
• Congenital anomaly/birth  defect  
Important medical events that may not result in death, are life -threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to  prevent one of the outcomes listed  in this definition.  Examples  of such 
medical events include allergic bronchospasm requiring intensive treatment in an  
emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization,  or the development of drug dependency  or drug abuse. 
All adverse events of osteosarcoma will be reported as SAEs. All reports of  
osteosarcoma, regardless of causality or expectedness, will be expedited to the FDA  
within 15 days of receipt. MedDRA preferred terms include osteosarcoma, osteosarcoma metastatic,  osteosarcoma  recurrent,  extraskeletal osteosarcoma,  extraskeletal  
osteosarcoma metastatic,  extraskeletal osteosarcoma recurrent.  
All SAEs must be followed until resolution (subject has returned to baseline status of 
health)  or until stabilization  (the Investigator does not expect  any further improvement or 
worsening of the reported event). 
 
8.1.3. Recording  Adverse Events  
All AEs/SAEs  will be entered  into the electronic database.  
Planned hospital admissions or surgical procedures for an illness or disease that existed 
before the subject was enrolled in the study are not to be considered AEs unless they occur at a time other than the planned date or the pre-existing illness or disease worsens after enrollment into the  study. 
Fractures identified during the study are not to be recorded as AEs unless the subject is hospitalized, the fracture  is complicated,  or the Investigator considers the fracture  to be 
unrelated to the subject’s underlying osteoporosis. All fractures will be identified and  
evaluated as part of the disease assessment and will be documented in the case report  
form  and by collection of source documents. 
For both serious and  non-serious adverse events,  the Investigator  must determine  the 
intensity of the event and the relationship of the event to study drug administration. Intensity  for each AE  will be defined  according to the following criteria:  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  49 of 60  
  
 
Intensity  Definition  
 
Mild  Awareness  of sign or symptom, but easily  tolerated.  
 
Moderate  Discomfort enough to cause interference with normal daily 
activities.  
 
Severe  Inability  to perform normal daily activities.  
 
If the intensity of an adverse event changes within a day, the maximum intensity should  
be recorded. If the intensity changes over a longer period of time, the changes should be 
recorded  as separate events  (having separate onset and stop dates for  each intensity).  
Relationship  to blinded study drug administration  will be determined  by the Investigator 
according  to the following  criteria:  
 
Relationship  Definition  
 
None No relationship  between  the event  and the 
administration of study drug. The event is related to other etiologies, such as concomitant medications  or subject’s  
clinical  state.  
 
Unlikely  The current state of knowledge indicates  
that a relationship to study drug is unlikely or the temporal relationship is such that study drug would not have had any reasonable association with the observed event.  
 
Possible A reaction  that follows a plausible temporal  
sequence from administration of the study drug and follows a known response pattern to the suspected study drug. The reaction might have been produced by the subject’s clinical state or other modes of therapy  
administered  to th e subject.  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  50 of 60  
  
Relationship  Definition  
 
Probable A reaction  that follows a plausible temporal  
sequence from administration of the study 
drug and follows a known response pattern to the suspected study drug. The reaction cannot be reasonably explained by the known characteristics of the subject’s clinical state or other modes of therapy  
administered  to the subject. 
 
For the purpose of safety analyses, all AEs that are classified with a relationship to study  
medication administration of possible or probable will be considered treatment- related  
events.  
 
8.1.4. Serious  Adverse Event  (SAE) Reporting  
Any SAEs that occur during the study from the t ime the subject signs the ICF until 30  
days after the last dose of study medication must be reported within 24 hours of first 
awareness of the event to RADIUS Pharmacovigilance. These events will be followed  
until resolution or stabilization. The reference safety information for this study is included in the Investigator Brochure, which  will be provided under separate  cover  to all 
Investigators. 
Any SAEs  that occur at  any time after  completion  of the study, which  the Investigator 
considers to be related  to study drug, must be reported  to the Sponsor or its designee.  
The Investigator must submit the SAE to the IRB in accordance with 21 CFR parts 56 
and 312 as  well  as with  applicable local  regulations. Documentation of these submissions 
must be retained in the site study  file. 
 
8.1.5. Follow- up of Adverse Events  
All AEs will be followed with  appropriate medical  management  until resolved  or 
stabilized.  
 
8.1.6. Abuse,  Misuse,  Overdose,  or Medication  Error  
Abuse, misuse, overdose or medication error (as defined below) must be reported to the 
Sponsor whether  or not they result in an AE/SAE.  
• Abuse – Persistent  or sporadic intentional intake of investigational medicinal  
product at a dose higher than prescribed per protocol (but below the dose defined for overdose) or when used for non-medical purpose (eg, altering one’s state of consciousness).  
• Misuse – Intentional or unintentional use of investigational medicinal product other than as directed or indicated at any dose, which is at or below the dose defined for overdose Note: this includes a situation where the test article is not used as directed at the dose prescribed by the protocol. 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  51 of 60  
 • Overdose – Intentional or unintentional injection of a dose of abaloparatide at 
least 2 times higher than the protocol specified dose and is associated with clinical  symptoms. 
• Medication Error – A mistake made in prescribing, dispensing, administration and/or use of the investigational medicinal product. 
 
8.1.7. Regulatory Agency,  Institutional  Review  Board, Ethics  Committee  and 
Site Reporting  
The Sponsor and/or the clinical contract  research organization  (CRO)  are responsible for 
notifying the relevant regulatory authorities/US central Institutional Review Boards  
(IRBs)/EU central ethics committees (ECs) of  related, unexpected SAEs. 
The Investigator  is responsible for notifying the Sponsor, CRO,  and local  IRB,  local  EC, 
or the relevant local regulatory authority of all SAEs that occur at his or her site as  
required. 
If a death occurs during the study or within 30 days after Month 3/Early Termination visit 
(Visit 5), and it is determined to be related either to a study procedure or study drug, the 
Investig ator or his/her designee must notify the Sponsor and will communicate that 
information to the IRB within one business day of knowledge of the event. The contact 
may be by phone or e- mail.  
8.2. Study  Completion  and Post-Study  Treatment  
The Investigator must provide follow- up medical care for all subjects who are 
prematurely  withdrawn  from the study due to  an adverse event or must refer them for 
appropriate ongoing care.  
 
8.3. Lost  to Follow -up 
For subjects whose status is unclear because they fail to appear for study visits without stating an intention to discontinue or withdraw, the Investigator should show "due diligence" by documenting in the source documents steps taken to contact the subject, eg, dates of telephone calls, registered letters, etc. A subject s hould not be formally 
considered lost to follow-up until his/her scheduled end of study visit would have occurred.  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  52 of 60  
  
9. STATISTICAL  CONSIDERATIONS  
9.1. Statistical Analysis Plan  
A comprehensive Statistical Analysis Plan (SAP)  will be completed  and approved prior 
to database lock. All statistical tests will be two -sided with a significance level of 5%, 
unless otherwise specified.  
 
9.2. Statistical Hypothesis 
9.3. Analysis Datasets  
9.3.1. Population for Analysis 
The primary population for all efficacy analyses will be the Bone-Biopsy Population, 
which is defined as all enrolled subjects who received a biopsy. The primary population for all safety  analyses will  be the Safety  Population, which will be  defined  as all enrolled  
subjects  who received  at least one dose of abaloparatide.  
9.4. Description  of Statistical Methods  
9.4.1. General  Approach  
Baseline is defined as  the last  value obtained prior to the first dose of study medication.  
For categorical data, summary tabulations of the number and percentage of subjects  
within  each category  of the parameter  will be  presented. For continuous data, the number 
of subjects, mean, median, standard deviation (SD), minimum, interquartile range (Q1 
and Q3), and maximum will be  presented.  
 
9.4.2. Analysis of the Primary  Efficacy  Endpoint(s)  
The primary endpoint of this study is the change from baseline to 3 months in 
mineralizing surface (MS/BS) in the cancellous bone envelope. Paired t- tests will be used  
to compare the differences in dynamic indices between the t wo time -points derived from 
the two sets of double labels using the Bone-Biopsy Population. If the normality assumption of the efficacy data is not satisfied at the 0.01 significance level and if visual inspection of the data deems it necessary, an appropr iate nonparametric test, such as the 
Wilcoxon signed-rank test, will be used to assess changes from baseline. No adjustments for multiplicity  will be made. A  p-value < 0.05 will be  considered statistically  significant.  
9.4.3. Analysis of Secondary  Endpoint(s)  
Secondary efficacy endpoints of tissue-based indices of bone formation and bone 
resorption will be analyzed in  the same manner as  the analysis of the primary  efficacy  
endpoint using the Bone Biopsy Population. 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  53 of 60  
 The change and percent change from baseline in bone turnover makers (s- PINP and  
s-CTX) will be summarized descriptively at each visit (1 and 3 months) using the 
Bone-Biopsy and the Safety  Populations. 
Linear regression analyses will be used to assess the relationships between efficacy  
endpoints of tissue-based indices of bone formation and bone resorption and changes in bone turnover markers at each visit, including changes in MS/BS and BFR/BS in each envelope to changes in s- PINP, changes in intracortical  MS/BS and BFR/BS to changes 
in s-CTX, MS/BS and BFR/BS in each envelope at Month 3 to s-PINP at Months 1 and 3, intracortical MS and BFR/BS at Month 3 to s-CTX at Month 3, and ES/BS in each envelope and cortical porosity at Month 3 to s-CTX at Month 3. The analyses include scatter plots, Pearson’s correlation coefficient, and slopes of simple regression models using the Bone-Biopsy Population. 
 
9.4.4. Safety  Analyses 
Unless  otherwise specified, safety  analyses  will be  conducted using the Safety  Population 
and will be descriptive in  nature.  
Study drug exposure and  study drug compliance will be calculated.  The duration of study 
drug exposure, total dose received, and percent compliance will be summarized.  
All AEs will be coded using MedDRA. The number and percent of subjects who experienced  treatment -emergent  AEs  (TEAEs)  will be summarized  by MedDRA system  
organ class (SOC), and preferred term (PT). Summaries will also be provided for severe 
TEAEs, serious TEAEs (SAEs), TEAEs leading to study drug withdrawal, drug- related  
TEAEs (with probable or possible relationship to study drug), and TEAEs by maximum severity  (mild, moderate,  severe).  
The number and percent of subjects who report TEAEs associated with hypercalcemia and hypercalciuria will be summarized.  
All AEs collected  prior to  the first dose of study drug will be  summarized separately.  
Descriptive  statistics  for clinical  laboratory data (including serum  calcium  and albumin), 
vital signs (including blood pressure), ECGs, and Investigator assessment of local  
tolerance will be provided by visit. For laboratory data, vital signs and ECGs, absolute results and changes from baseline will be presented. In addition, laboratory test results will be classified as  above normal limit,  within normal l imit, or  below normal limit.  
Laboratory shift frequencies will be tabulated between the Screening visit and relevant post- baseline visit(s).  
Concomitant medications will be coded using the WHO Drug Dictionary and summarized by number and percentage of subjects using each class and preferred drug term.  
 
9.4.5. Adherence and Retention  Analyses 
The number and percentage of subjects who withdraw from the study, with primary reason,  will be summarized.  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  54 of 60  
 9.4.6. Baseline  Descriptive Statistics  
Medical history, physical examination, demographics and baseline characteristics will be 
summarized and presented. Medical history will be presented by MedDRA SOC and PT, summarizing the proportion of subjects who have a condition noted. Results from the baseline physical examination will be summarized by body system as recorded in the eCRF.  
9.4.7. Interim  Analyses 
There are no interim analyses planned  for this study. 
 
9.4.8. Tabulation of Individual  Response  Data  
Individual efficacy  and safety  data will be  tabulated as  appropriate.  
 
9.5. Sample  Size Calculation  
In the AVA study of teriparatide and denosumab ( Dempster, 2016 ), the mean (± SD)  
change from baseline in cancellous MS/BS (%) for teriparatide was 13.90 (± 9.38) at 
3 months. In  the ACTIVE study, the median %  change from  baseline in s- PINP  at 
3 months was  60% for abaloparatide and  94% for teriparatide.  The ratio between  the 2 
groups is approximately  2/3 (= 60%/94%). 
Using  the same ratio and the results  for teriparatide  obtained from  the AVA study, we  can 
assume that the mean change from baseline in cancellous MS/BS (%) for abaloparatide at  
3 months will be 9.2% (= 13.90*2/3). Assuming a standard deviation (SD) of 12.0%, a sample size of 21 completers will provide at least 90% power to detect a statistically  
significant change from baseline in cancellous MS/BS (%) for abaloparatide at 3 months of 9.2%. The study is planned to enroll approximately 25 subjects to accommodate a 
drop-out rate of 15%, including those with non-evaluable bone biopsy. Additional 
subjects  may  be enrolled  if the  number of evaluable biopsies is insufficient to achieve this 
power. 
 
9.6. Measures  to Minimize  Bias 
Not applicable.  
 
9.7. Enrollment/Randomization/Masking  Procedures  
Not applicable.  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  55 of 60  
  
10. ADMINISTRATIVE  REQUIREMENTS  
10.1. Ethical Considerations  
This clinical study will be conducted in accordance with the current version of ICH 
Harmonized Tripartite Guidelines for Good Clinical Practice (GCP), with applicable  
local  laws  and regulations, and  with  the ethical  principles laid  down in  the Declaration of  
Helsinki.  
The Investigator will ensure that this study is conducted in full conformity with 
Regulations for the Protection of Human Subjects of Research codified in 21 CFR Part  
50, 21 CFR Part 54, 21 CFR Part 56, 21 CFR Part 312, 21 CFR Part 314, and ICH GCP 
E6. 
The IRB will review all appropriate study documentation to safeguard the rights, safety, and well -being of the subjects. The study will only be conducted at sites wh ere IRB  
approval has been  obtained. The protocol, IB, ICF, advertisements  (if applicable),  written  
information given to the subjects, safety updates, annual progress reports, and any 
revisions to these documents will be provided to the IRB by the Investiga tor or RADIUS  
or designee,  as allowable  by local applicable laws  and regulations. 
10.2. Subject  Information  and Informed  Consent  
The Investigator is  responsible for obtaining written,  informed  consent from  each  subject  
interested in  participating in this study before  conducting any study- related  procedures. 
Written informed consent should be obtained after adequate, thorough, and clear 
explanation of the study objectives, procedures, as well as the potential hazards of the study. The  method of obtaining and documenting the informed consent and  the contents 
of the consent will comply with ICH GCP and all applicable laws and regulations and will be subject to approval by RADIUS or its designee. 
10.3. Investigator  Compliance  
No modifications to the protocol should be made without the approval of both the Investigator and RADIUS. Changes that significantly affect the safety of the subjects, the scope of the investigation, or the scientific quality of the study (ie, efficacy assessments) will require IRB notification before implementation, except where the modification is  
necessary to eliminate an apparent immediate hazard to human subjects. RADIUS will  
submit all protocol modifications to the  required  regulatory authorities.  
When circumstances require an immedi ate departure from procedures set forth in the 
protocol, the Investigator will contact  RADIUS  to discuss the planned course of action.  If 
possible, contact should be made before the implementation of any changes. Any departures  from protocol must be fully  documented in the source documentation. 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  56 of 60  
 10.4. Access  to Records  
The Investigator must make the office and/or hospital records of subjects enrolled in this 
study available for review by site monitors at the time of each monitoring visit, audit by RADIUS QA and inspection by the regulatory agencies. The records must also be available for inspection, verification, and copying, as required by applicable laws and regulations, by officials of the regulatory health authorities (FDA and others). The Inves tigator must comply with applicable privacy and security laws for use and 
disclosure of information related  to the research set  forth in this protocol. 
 
10.5. Subject  Data  Confidentiality  
To maintain subject confidentiality, all eCRFs, study reports and communications relating to the study will identify subjects by assigned subject numbers. As required by federal  regulations, the Investigator will allow  RADIUS  and/or its representatives  access  
to all pertinent medical records to allow for the verification of data  gathered in the 
eCRFs/SAE Forms and the review of the data collection process. The FDA (or other regulatory authority) may also request access to all study records, including source documentation, for inspection. 
As applicable,  in accordance with the Health  Insurance Portability  and Accountability  
Act (HIPAA) and associated privacy regulations, a subject authorization to use personally 
identifiable health information may be required from each subject before research  
activities  begin. 
Subject confidenti ality is strictly held in trust by the participating Investigators, their  
staff, and RADIUS and their representatives. This confidentiality is extended to cover 
testing of biological samples and genetic tests in addition to the clinical information  
relatin g to participants.  Therefore,  the study protocol, documentation, data,  and all other 
information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third party without prior wri tten 
approval of RADIUS.  
 
10.6. Research  Use of Stored  Human  Samples,  Specimens,  or Data  
With the subject’s approval, and as approved by the site’s IRB, biological samples may 
be stored at a centralized facility  determined  by RADIUS. These  samples could be used  
for retrospective biomarker research or analysis of clinical response to therapy. The 
storage facility will be provided with a code- link that will allow linking the biological 
specimens with the phenotypic data from each subject, maintaining the masking of the identity  of the subject.  
During the conduct of the study, any individual subject  can choose to withdraw  consent 
to have biological specimens stored for future research. When the study is completed, access  to study data and/or samples will be  provided through RADIUS. 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  57 of 60  
 10.7. Data  Quality Assurance  
RADIUS or its designated representative will conduct a study site visit to verify the  
qualifications  of each Investigator, inspect  clinical  study site facilities  as needed, and  
inform the Investigator of responsibilities and procedures for ensuring adequate and 
correct study documentation. 
The Investigator is required to prepare and maintain adequate and accurate case histories  
designed to record all observations and other data pertinent to the study for each study 
subject. Study data for each enrolled subject will be entered into an eCRF by site personnel using a secure,  validated  web -based electronic data capture (EDC) application. 
RADIUS  will have  read-only access to all data upon entry  in the EDC application. 
Instances of missing, discrepant, or uninterpretable data will be queried with the Investigator for resolution. Any changes  to study data will be  made to the eCRF  and 
documented in  an audit trail, which  will be maintained  within  the clinical  database.  
To ensure compliance with GCP and all applicable regulatory requirements, a quality 
assurance audit may be conducted. Regulatory agencies may also conduct a regulatory inspection of this study. Such audits/inspections can occur at any time during or after completion of the study. If an audit or inspection occurs, the Investigator and institution agree to allow  the auditor/inspector direct  access  to all relevant  documents and  to allocate 
his/her time and the time of his/her staff to the auditor/inspector to discuss findings and any relevant issues. In the case of an audit or inspection, the Investigator or a delegate will alert RADIUS, as  soon as he/she becomes aware of the audit or inspection. 
The Investigator and study staff are responsible for maintaining a comprehensive and 
accurate filing system of all study -related documentation that will be suitable for  
inspection at  any time by RADIUS, its  designees,  and/or regulatory agencies.  In signing 
this protocol, the Investigator understands and agrees to give access to the necessary  
documentation and files.  
10.8. Monitoring  
RADIUS is responsible for ensuring the proper conduct of the study with regard to 
protocol adherence and validity of data recorded in the clinical database. The study will be monitored by RADIUS or its designee. Monitoring will be done by personal visits from a representative of RADIUS, or designee (site monitor), who will review the eCRFs, SAE Forms and source documents. The site monitor will ensure that the invest igation  is conducted according  to the protocol design and regulatory requirements.  
 
10.9. Data  Collection  and Management  Responsibilities  
Data collection is the responsibility of the clinical study staff at the site under the  
supervision of the Investigator. The  Investigator is  responsible for ensuring the accuracy,  
completeness,  legibility,  and timeliness  of the data reported.  
RADIUS will provide the study sites with secure access to and training on the EDC  
application sufficient to permit site personnel to enter and correct information in the 
eCRFs  on the subjects for which they are responsible for. 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  58 of 60  
 An eCRF  will be completed  for each  subject  who  receives  at least  one dose of study drug. 
It is the Investigator's responsibility to ensure the accuracy, completeness, clarity, and 
timeliness of the data reported in the subject’s eCRF. Source documentation supporting the eCRF data should indicate the subject’s participation in the study and should document the dates an d details of study procedures, AEs, other observations, and subject 
status.  
The Investigator, or designated representative, should complete the eCRF in a timely 
manner  after information is collected.  
The audit trail entry will show the user's identificatio n information and the date and time 
of any correction. The Investigator must provide formal approval of all the information in the eCRFs, including any changes made to the eCRFs, to endorse the final submitted data for the subjects for whom the Investigator is responsible. 
RADIUS  will retain  the eCRF  data,  queries  and corresponding audit trail.  A copy of the 
final archival eCRF in the form of a compact disc or other electronic media will be  
provided to the site  for placement in  the Investigator's study file. 
 
10.10.  Study  Records  Retention 
The Investigator will maintain study documents for a minimum of 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applica tions in an ICH region or until at least 2 years have 
elapsed since the formal discontinuation of clinical development of the investigational product. These documents should be retained for a longer period, however, if required by local regulations. If the Investigator withdraws from the responsibility of keeping the study records, custody must be transferred to a person willing to accept the responsibility 
and RADIUS must be notified. No records will be destroyed without the written consent 
of RADIUS.  
10.11.  Publ ication  and Data  Sharing  Policy  
Publication of complete data from the study is planned. It is anticipated that the results of this study will be presented at scientific meetings and/or published in a peer reviewed scientific or medical journal. A Publications Committee composed of Investigators participating in  the study and representatives  from  RADIUS  as appropriate will be 
formed  to oversee the publication of the study results,  which will reflect the experience of 
all participating  study centers.  
Subsequently, individual Investigators may  publish results  from  the study in compliance 
with their agreement with RADIUS.  
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  59 of 60  
  
REFERENCES 
Bilezikian  JP. Anabolic therapy for osteoporosis. Women’s Health (Lond). 2007;3:243- 
253. 
 
Bone HG, Cosman F. Miller PD, Williams GC, Hattersley G, Hu M-y, Fitzpatrick LA. 
Papapoulos S. Sustained fracture risk reduction with sequential abaloparatide/alendronate: results of ACTIVExtend. ASBMR 2017 Annual Meeting. 1074. Abstract.  
 
Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis  
BJ, Christiansen C, B ilezikian JP, Black D. Eighteen months of treatment with  
subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women  with osteoporosis: results  of the ACTIVExtend  Trial.  Mayo  Clin  
Proc.  2017;92:200-210. 
 
Dempster D W, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic 
K, Muller R, Bilezikian J, Lindsay R. Effects of daily treatment with parathyroid 
hormone on bone architecture and turnover in subjects with osteoporosis: a paired biopsy study. J Bone Miner  Res.  2001;16:1846-1853. 
 
Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, 
Meunier  PJ, Ott SM,  Recker  RR, Parfitt  AM.  Standardized  nomenclature,  symbols, and 
units for bone histomorphometry: a 2012 update of the report of the ASBMR  
Histomorphometry Nomenclature  Committee. J  Bone Miner  Res. 2013;28:2-17. 
 
Dempster  DW,  Zhou H, Recker  RR, Brown  JP, Recknor CP, Lewiecki  EM,  Miller  PD, 
Rao SD, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Janos B, Ruff VA. 
Differential eff ects of teriparatide and denosumab on intact PTH and bone formation 
indices:  the AVA osteoporosis study. J Bone Miner  Res. 2016;101:1353-1363. 
 
Dempster D, Zhou H, Recker R, Brown J, Recknor C, Lewiecki EM, Miller P, Rao S, Kendler D, Lindsay R, Krege J, Alam J, Taylor K, Ruff V. Longitudinal changes in modeling- and remodeling-based bone formation with an anabolic vs. antiresorptive agent  in the AVA Osteoporosis Study. ASBMR  2016 Annual Meeting.  S51. Abstract.  
 
Dempster  DW,  Zhou H, Recker  RR, Brown  JP, Recknor CP, Lewiecki  EM,  Miller  PD, 
Rao SD, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Melby TE, Ruff VA. 
Remodeling- and Modeling- Based Bone Formation With Teriparatide Versus  
Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study. J Bone Miner Res. 2017 Oct 12. doi: 10.1002/jbmr.3309. 
 
Genant  HK,  Wu CY,  van Kuijk  KC,  Nevitt MC.  Vertebral  fracture assessment  using a 
semiquantitative  technique. J Bone Miner  Res. 1993;8:1137-1148. 
Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020, Amendment  2 Page  60 of 60  
 Hattersley G, Dean T, Corbin BA., Bahar H, Gardella TJ. Binding selectivity of 
abaloparatide for PTH -type-1- receptor  conformations and effects  on downstream  
signaling. Endocrinology. 2016;157:141-149. 
 
Lindsay R, Cosman F, Zhou H, Bostrom MP, Shen VW, Cruz JD, Nieves JW, Dempster  
DW. A novel tetracycline labeling schedule for longitudinal evaluation of the short- term 
effects of anabolic therapy with a single iliac crest bone biopsy: early actions of 
teriparatide.  J Bone Miner Res. 2006;21:366-373. 
 
Litwic  A, Lekarz,  Warwick  D, Denniston E.  Distal radius fracture:  Cinderella  of the 
osteoporotic fractures. Orthop Muscul Syst. 2014; 3:162-168. 
Makino, A., Takagi, H., Sugiyama, H. Effects of Abaloparatide on the Expression of 
Bone Resorption-and Formation -related Factors in Osteoblastic Cells; a Comparison with  
Teriparatide.  J Bone Miner  Res, 30 (Suppl 1). 
Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P,  
Zerbini CA, Hu M, Harris AG, Fitzpatrick LA, Cosman F, Christia nsen C. Effect of  
abaloparatide vs placebo on new vertebral fractures in postmenopausal women with 
osteoporosis: a randomized clinical trial. JAMA.  2016;316:722-733. 
Moreira CA, Fitzpatrick LA, Wang Y, Recker RR. Effects of abaloparatide-SC (BA058) 
on bone histology and histomorphometry: the ACTIVE  phase 3 trial. Bone. 
2017;97:314-319. 
 
Rizzoli  R. Osteoporosis, genetics and  hormones. J Mol Endocrinol. 2001;26:79-94. 
 
Rosen  CJ. Clinical practice. Postmenopausal  osteoporosis. N Engl J Med.  2005;353:59 
 
Rubin MR,  Dempster  DW,  Sliney  J Jr, Zhou H, Nickolas TL,  Stein  EM,  Dworakowski 
E, Dellabadia M, Ives R, McMahon DJ, Zhang C, Silverberg SJ, Shane E, Cremers S, Bilezikian  JP. PTH(1 -84) administration  reverses  abnormal bone-remodeling 
dynamics and structure in hypoparathyroidism. J Bone Miner Res. 2011 Nov;26(11):2727-36. 
 
World  Health  Organization  (2007) 
 
  
08-Nov -2018  16:59:33  GMT+0000  Approval  
 
09-Nov -2018  13:00:59  GMT+0000  Approval   
 
Signature  Page for RAD -CLIN- 000924 v4.0 
 
 
 
Signature  Page for RAD -CLIN- 000924 v4.0 

Radius Health, Inc.  
Abaloparatide -SC Confidential   
  
Radius Health, Inc. (RADIUS) 
950 Winter  Street, Waltham,  MA 02451 
USA  
 
 
Abaloparatide -SC 
 
Addendum to 
CLINICAL STUDY PROTOCOL:  BA058- 05-020 
 
An Open-label, Single- arm, Multicenter Study to Evaluate the Early Effects of  
Abaloparatide on Tissue -based  Indices  of Bone Formation and Resorption  
 
This study will be conducted according  to the protocol and in compliance with Good  Clinical  
Practice, the ethical principles stated in the Declaration of Helsinki, and other applicable  
regulatory requirements.  
 
 
Document  type:  Clinical Study  Protocol  Addendum 
 
IND number  73,176 
 
Version  number:  Version  3.0 (14 November 2018) 
Development  phase:  3 
 
Study  Site:   
 
  
 
 
Confidentiality Statement 
The information in this document contains trade secrets and/or commercial information 
that are privileged or confidential and may not be disclosed unless such disclosure is 
required by applicable law or regulations. In any event, persons to whom the information 
is disclosed  must be informed  that the information  is privileged or confidential and  may  
not be further disclosed by them. These restrictions on disclosure will apply equally to all 
future  information supplied to you which  is indicated  as privileged or confidential. 
 
 
 
Study  BA058-05-020 Addendum  

Radius Health, Inc.  
Abaloparatide -SC Confidential  
Study  BA058 -05-020 Addendum   
  
TABLE OF CONTENTS  
Radius Health, Inc. (RADIUS)  ........................................................................................................1 
Addendum to  ....................................................................................................................................1 
An Open -label,  Single- arm, Multicenter  Study to Evaluate the Early  Effects  of 
Abaloparatide on Tissue -based Indices  of Bone Formation and  Resorption................1 
Confidentiality  Statement  ................................................................................................................1 
TABLE OF CONTENTS  .................................................................................................................2 
PURPOSE O F THIS  ADDENDUM  ................................................................................................3 
STUDY SCHEDULE  ......................................................................................................................4 
Screening  (Visit 1)  ...........................................................................................................................4 
Pretreatment  (Visit 2)  .......................................................................................................................5 
Treatment  Period  ..............................................................................................................................6 
Day 1 (Visit 3) .................................................................................................................................6 
Month 1 (Visit 4)  .............................................................................................................................7 
Month 3 (Visit 5)  .............................................................................................................................7 
Month 4 (Visit 6)  .............................................................................................................................8 
Month 6/Early Termination (Visit 7)  ...............................................................................................8 
Month 7 (Visit 8)  .............................................................................................................................9 
Unscheduled Visit ............................................................................................................................9 
DISCONTINUATION FROM THE  STUDY  ...............................................................................10 
LIST  OF TABLES 
Table 1: Schedule of Assessments  and Procedures  .................................................................. 12 
Radius Health, Inc.  
Confidential  Abaloparatide -SC 
Study  BA058 -05-020 Addendum   
  
 
1. PURPOSE  OF THIS  ADDENDUM  
This is a single -site Addendum that applies to , based on Clinical 
Study Protocol BA058- 05-020 Version 3.0, dated 14 November 2018. 
Study assessments and procedures have been modified as follows and are presented in the 
Schedule of Assessments and Procedures ( Table 1 ). 
The treatment period  is extended  to six (6) months 
1. Additional visits  at Month 6 (Visit 7)  and Month 7 (Visit 8) are  added  
2. Peripheral quantitative computed tomography (pQCT) of the forearm and tibiae is 
added  at Pretreatment (Visit 2),  Month  3 (Visit  5), and Month 6 (Visit 7) 
3. “Discontinuation from  the Study” has been  updated to reflect  the modified  visit 
schedule 
4. Early termination procedures have been updated to reflect the extended treatment 
period. 

Radius Health, Inc.  
Confidential  Abaloparatide -SC 
Study  BA058 -05-020 Addendum   
  
 
 
2. STUDY  SCHEDULE  
This study addendum is comprised of seven clinic visits. Study assessments are to be 
performed according to the Schedule of Events ( Table 1 ). There is a ± 4 -day window for 
each clinic visit, other than Day 1 for which there is a +4-day window and Month 7 (Visit 
8) for which  there  is a ±  7-day window. 
The study will consist of a Screening Period (up to 1 month), a Pretreatment Period 
(approximately 1 month), a Treatment Period (6 months), and a Month 7 Visit (one month). During the Treatment Period, subjects will have clinic visits for study- related  
protocol procedures at Day 1, Month 1, Month 3, Month 4, and Month 6. For the 
purpose of this study, one month is equal to 30 days. 
Subjects consenting under the addendum will have data collected according to the length 
of their  participation.  An addendum subject  who terminates  at or before  the Month 3 
Visit will return for assessments as indicated in the Addendum Sch edule of Assessments  
and Procedures for the Month 3 Visit and complete the study 30 days later at the Month 4 
Visit (See Section 2.6 of the main protocol). Subjects who decide they do not wish to participate in the study following the Month 3 Visit should return for assessments as  
indicated in the Addendum, Schedule of Assessments and Procedures for Month 6/Early Termination Visit and 30 days later for the Month 7 Visit ( see Section 2.9 of the main  
protocol). 
 
2.1. Screening  (Visit  1) 
Signed informed consent will be obtained and eligibility for study entry assessed. Subjects 
who are eligible for the study on the basis of screening evaluations will enter the 
Pretreatment Period  of the study, and will be provided calcium  and vitamin  D 
supplements. This should be continued through the Treatment Period according to the 
subject’s need, so that they have an intake of at least 1200 mg/day of calcium and 800- 
1000 IU/day of vitamin D. Vitamin D supplements are required to be administered daily 
from the Pretreat ment Period until the end of the Treatment Period. Calcium will also be  
administered daily, with the exception of the days of administration of demeclocycline and tetracycline, where calcium administration will be withheld. The following baseline  
screening  evaluations will be performed: 
• Obtain  Informed  Consent 
• Verification  of study entry  criteria  
• Review  of medical history  
• Physical  examination  
• Blood pressure  and vital signs (see  Section  7.3 of main protocol) 
• Weight  and height (see  Section  7.3 of main protocol) 
• 12-lead ECG  
• Laboratory testing  of serum  chemistry,  hematology, urine dipstick, and coagulation 
Radius Health, Inc.  
Confidential  Abaloparatide -SC 
• Drug  accountability  
Study  BA058 -05-020 Addendum   
  
• PTH,  25-hydroxyvitamin D,  and 1,25-dihydroxyvitamin D levels  
• FSH and TSH levels  
• Lumbar and thoracic spine radiographs (anteroposterior and lateral)  
• BMD assessments of lumbar spine, total hip and femoral neck by dual X- ray 
absorptiometry (DXA)  
• AE and concomitant medication  review  from  signing of the informed  consent 
• Dispense vitamin  D and  calcium  
Subjects whose laboratory tests do not fall within the specified ranges as detailed in the 
inclusion/exclusion criteria may have the samples redrawn and the tests repeated within 30 
days of the original test date. If upon reanalysis, the values fall within the 
inclusion/exclusion criteria, the subject may enter the study. Subjects who do not meet the 
25-hydroxyvitamin D entry criterion may receive vitamin D supplementation and be retested one time. Similarly, subjects with minor elevations of PTH may be retested one  
time after vitamin D supplementation. All subjects enrolled following retesting must have  
safety  laboratory results reported within 30 days prior to  enrollment.  
All AEs, including serious adverse events (SAEs), will be recorded from the time of 
signing of the informed consent and through the 30 days after the last dose of study medication.  
 
2.2. Pretreatment  (Visit  2) 
All subjects will receive calcium and vitamin D until the end of the Treatment Period,  
according to the subject’s need so that they have an intake of at least 1200 mg/day of 
calcium and 800-1000 IU/day of vitamin D. Subjects should be on a stable dose of 
calcium  and vitamin  D for 30 days prior to  initiating  the double labeling  procedure. 
Subjects will undergo training for medication self- administration and for completion of 
diary, to include administration  of medications  for bone biopsy labeling  procedure. 
Vitamin D supplements are required to be administered daily from the Pretreatment Period until the end of the Treatment Period. Calcium will also be administered daily, with the exception of the days of administration of demeclocycline and tetracycline where 
calcium  administration  will be withheld. The  following procedures will be performed:  
• Verification  of study entry  criteria  
• Review  of medical history  
• Symptom directed  physical exam  (see Section  7.3 of main  protocol) 
• Blood pressure  and vital signs (see  Section  7.3 of main protocol) 
• Peripheral  quantitative  computed tomography (pQCT) of the forearm  and tibiae  
• Clinical assessment  of new  fractures  
• AE and concomitant medication  review  
• Dispense demeclocycline,  vitamin  D and calcium  
Radius Health, Inc.  
Confidential  Abaloparatide -SC 
• Drug  accountability  
Study  BA058 -05-020 Addendum   
  
• Subject  injection  training  
Eighteen (18) days before Day 1 of the Treatment Period (Visit 3), subjects who remain 
eligible for study participation will begin the first bone biopsy labeling procedure with 
administration of 150 mg demeclocycline 4 times daily for 3 days followed by a 12- day 
intermission,  and then  demeclocycline for  3 additional days at  the same dose. 
Demeclocycline should be taken on an empty stomach, at least 1 hour before meals and 2 
hours after  a meal with a  full glass of water.  
 
2.3. Treatment Period  
At each cl inic visit during the Treatment Period, recent health status will be obtained, the 
diary reviewed, adverse events and concomitant medications collected, drug supply / resupply and accountability, and blood pressure and vital signs performed. Laboratory 
assessments of serum chemistry, hematology and urinalyses will be obtained at Day 1, 
Month 1, Month 3, and Month 6. Clinical assessments for fracture will be performed at 
each visit. Source documentation (imaging report and/or film along with other supporting 
documentation as appropriate) will be collected from each site to confirm fracture. If the subject reports that a fracture has occurred, remind the subject to bring X-rays and any 
medical  reports of the fracture  to the next clinic visit.  Documentation must be obtained 
on all new fractures that occur during the study. This documentation should be 
maintained  in the source documents. 
Bone turnover marker assessments (s -PINP and s-CTX) will be performed on the Day 1, 
Month 1 and Month 3 visits (Visits 3,  4, and 5, respectively). 
 
2.4. Day 1 (Visit  3) 
• Review  of medical history  
• Symptom directed  physical exam  (see Section  7.3 of main  protocol) 
• Blood pressure  and vital signs (see  Section  7.3 of main protocol) 
• Weight  and height measurement  (see Section  7.3 of main  protocol) 
• 12-lead ECG  
• Laboratory testing  of serum  chemistry  (pre-dose), hematology, and urine dipstick 
• Bone turnover markers  (s-PINP  and s-CTX)  
• Clinical assessments of new  fractures  
• Collect  blood for immunogenicity  testing  
• Subject  diary  review  
• AE and concomitant medication  review  
• Dispense abaloparatide,  vitamin  D and calcium  
• First dose of abaloparatide will be administered  by the subject  in clinic  
• Investigator assessment  of local  tolerance after  injection  
Radius Health, Inc.  
Confidential  Abaloparatide -SC 
Study  BA058 -05-020 Addendum   
  
2.5. Month  1 (Visit  4) 
• Review  of medical history  
• Symptom directed  physical exam  (see Section  7.3 of main  protocol) 
• Blood pressure  and vital signs (see  Section  7.3 of main protocol) 
• Weight  and height measurements  (see Section  7.3 of main  protocol) 
• Laboratory testing  of serum  chemistry  (predose),  hematology, and urine dipstick  
• Bone turnover markers  (s-PINP  and s-CTX)  
• Clinical assessment  of new  fractures  
• Review  subject  diary  
• AE and concomitant medication  review  
• Dispense abaloparatide,  vitamin  D, calcium  and tetracycline  
• Self-administration of study medication when directed by site staff after completion of 
predose activities  
• Investigator assessment  of local  tolerance after  injection  
• Drug  accountability  
Approximately twenty- three (23) to twenty -six (26) days prior to Visit 5, subjects will begin the 
second bone biopsy labeling procedure with administration of 250 mg tetracycline 4 times daily 
for 3 days followed by a 12-day intermission, and then tetracycline for 3 additional days at the 
same dose. Tetracycline should be taken on an empty stomach, at least 1 hour before meals and 2 
hours after  a meal with a  full glass of water.  
 
Note:  Subjects consenting under the addendum will have data collected according to the length 
of their participation. An addendum subject who terminates at or before the Month 3 Visit will 
return for assessments as indicated in the Addendum Schedule of Assessments and Procedures 
for the Month 3 Visit and  complete the  study 30 days later at  the Month 4 Visit ( Table 1).  
 
2.6. Month  3 (Visit  5) 
• Review  of medical history  
• Symptom directed  physical exam  (see Section  7.3 of main  protocol) 
• Blood pressure  and vital signs (see  Section  7.3 of main protocol) 
• Weight  and height measurements  (see Section  7.3 of main  protocol) 
• 12-l ead  ECG  
• Laboratory testing  of serum  chemistry  (pre-dose), hematology, and urine dipstick 
• Coagulation blood testing  
• PTH  level  
• Bone turnover markers  (s-PINP  and s-CTX)  
• Peripheral  quantitative  computed tomography (pQCT) of the forearm  and tibiae  
Radius Health, Inc.  
Confidential  Abaloparatide -SC 
Study  BA058 -05-020 Addendum   
  
• Clinical assessment  of new  fractures  
• Collect  blood for immunogenicity  testing  
• Review  subject  diary  
• AE and concomitant medication  review  
• Self-administration of study medication when directed by site staff after completion of 
predose activities  
• Investigator assessment  of local  tolerance after  injection  
• BMD assessments of lumbar spine, total hip and femoral neck by dual X- ray 
absorptiometry (DXA)  
• Transiliac crest bone biopsy 5-8 days after last tetracycline dose (Sponsor together with 
Medical Monitor should determine if included should an addendum subject terminate 
study participation after initiating  tetracycline labeling) 
• Dispense abaloparatide,  vitamin  D and calcium  
• Drug  accountability  
 
Note:  Subjects who decide they do not wish to participate in the study following the 
Month 3 Visit should return for assessments as indicated in the Addendum, Schedule of Assessments and Procedures for Month 6/Early Termination Visit and 30 days later for 
the Month 7 Visit ( Table 1).  
 
2.7. Month  4 (Visit  6) 
• Review  of medical history  
• Symptom directed  physical examination  (see Section  7.3 of main  protocol) 
• Blood pressure  and vital signs (see  Section  7.3 of main protocol) 
• Weight  and height measurements  (see Section  7.3 of main  protocol) 
• 12-lead ECG  
• Clinical assessment  of new  fractures  
• Review  subject  diary  
• AE and concomitant medication  review  
• Dispense abaloparatide,  vitamin  D and calcium  
• Self-administration of study medication when directed by site staff after completion of 
pre-dose activities  
• Drug  accountability  
• Investigator a ssessment  of local  tolerance after  injection  
 
2.8. Month  6/Early  Termination  (Visit  7) 
• Review  of medical history  
• Symptom d irected  physical exam  (see Section  7.3 of main  protocol) 
Radius Health, Inc.  
Confidential  Abaloparatide -SC 
Study  BA058 -05-020 Addendum   
  
• Blood pressure  and vital signs (see Section  7.3 of main  protocol) 
• 12-lead electrocardiogram  (ECG) 
• Laboratory testing  of serum  chemistry  (pre-dose), hematology, and urine dipstick 
• PTH  level  
• Peripheral  quantitative  computed tomography (pQCT) of the forearm  and tibiae  
• Clinical assessment  of new  fractures  
• BMD assessments of lumbar spine, total hip and femoral neck by dual X- ray 
absorptiometry (DXA)  
• Review  subject  diary  
• AE and concomitant medication  review  
• Self-administration of last dose of study medication when directed by site staff after 
completion  of pre-dose activities  
• Drug  accountability  
• Investigator assessment  of local  tolerance after  injection  
 
2.9. Month  7 (Visit  8) 
• Review  of medical history  
• Symptom directed  physical examination  (see Section  7.3 of main  protocol) 
• Blood pressure  and vital signs (see  Section  7.3 of main protocol) 
• Weight  and height measurements  (see Section  7.3 of main  protocol) 
• 12-lead electrocardiogram  (ECG) 
• Clinical assessment  of new  fractures  
• AE and concomitant medications review  
 
2.10. Unscheduled Visit  
If the subject returns to the clinic for an unscheduled visit (eg, to follow-up on an abnormal 
laboratory test), the procedures performed at this visit will be recorded in the eCRF and source 
documentation. 
Radius Health, Inc.  
Confidential  Abaloparatide -SC 
Study  BA058 -05-020 Addendum   
  
3. DISCONTINUATION FROM THE  STUDY  
Subjects  may voluntarily discontinue from  the study for any  reason  at any time.  
Subjects sustaining a radiologically confirmed incident vertebral fracture will be informed of the 
finding and will be counseled as to treatment options and may discontinue or choose to rem ain 
on the study.  Refer to Section 5.3.1 of the main  protocol for details.  
Subjects  who decide they do not wish  to participate  in the study at  or before  the Month 3 Visit  
will return for assessments as indicated in the Addendum Schedule of Assessments and  
Procedures  for Month 3 Visit and  complete the  study 30 days later at  the Month 4 Visit.  
Subjects  who  decide they do not wish  to participate  in the study following the  Month 3 
Visit should return for assessments as indicated in the Addendum, Schedule of Assessments and 
Procedures  for Month 6/Early Termination  and 30 days later  for the Month 7 Visit ( Table 1 ). 
If they fail to return for these assessments for unknown reasons, every effort to contact them (eg,  
by telephone, email, and letter for a minimum of three attempts) should be made and 
documented in the subject’s study file. 
Radius Health, Inc.  
Confidential  Abaloparatide -SC 
Study  BA058 -05-020 Addendum   
  
Table 1: Schedule  of Assessments and Procedures  
 
 
 
 
 
Procedure  Visit  1 Visit 2 (±4 
days)  Visit  3 
(+4 days)  Visit  4 
(±4 days)  Visit  5 
(±4 days)  Visit  6 
(±4 days)  Visit  7 
(±4 days)  Visit  8 
(±7 days)  
Screening  
(30 Days)  Pretreatment  Day 1 Month  1 Month  3 Month  4 Month  6 Month  7 
Informed  consent  X        
Verification  of entry  criteria  X X       
Review  of medical  historya X X X X X X X X 
Physical  examinationb X        
Symptom  directed  physical  examination   X X X X X X X 
Vital  signsc X X X X X X X X 
Weight  and height  measurementsd X  X X X X  X 
12-lead  Electrocardiograme X  X  X X X X 
Urinalysis  (dipstick)f X  X X X  X  
Chemistry  blood  collectiong X  X X X  X  
Hematology  blood  collection  X  X X X  X  
Coagulation  (PT and PTT)  blood  collection  X    X    
PTH (1-84) X    X  X  
25-hydroxyvitamin  D level  X        
1,25 -dihydroxy  vitamin  D level  X        
FSH X        
Thyroid  stimulating  hormone  X        
Injection  training  for subjects   X       
Dispense  calcium  and vitamin  D 
supplementsn X X X X X X   
Study  medication  (abaloparatide)  
administration    Daily  abaloparatide  administration   
Radius Health, Inc.  
Confidential  Abaloparatide -SC 
Study  BA058 -05-020 Addendum   
  
 
 
 
 
Procedure  Visit  1 Visit 2 (±4 
days)  Visit  3 
(+4 days)  Visit  4 
(±4 days)  Visit  5 
(±4 days)  Visit  6 
(±4 days)  Visit  7 
(±4 days)  Visit  8 
(±7 days)  
Screening  
(30 Days)  Pretreatment  Day 1 Month  1 Month  3 Month  4 Month  6 Month  7 
Demeclocycline  (dispense  and 
administration)   Xh       
Tetracycline  (dispense  and administration)     Xi     
Transiliac  crest  bone  biopsyj     X    
Serum  markers  of bone  metabolism  (PINP  
and CTX)    X X X    
AP and lateral  lumbar  and thoracic  spine  
radiographs  X        
Peripheral  quantitative  computed  
tomography  (pQCT)  of the forearm  and tibiae   X   X  X  
Clinical  assessment  of new  fracturesk  X X X X X X X 
Collect  blood  for immunogenicity  testing    X  X    
BMD  of lumbar  spine,  total  hip, and femoral  
neck  X    X  X  
Investigator  assessment  of local  tolerance  
(dermal reactions  assessment)   X X X X X  
Subject  diary  reviewl   X X X X X  
Document  AEs and concomitant  
medicationsm At any time,  question  subject  at each  visit 
Drug  supply/resupply/accountability   X X X X X X  
a Including  alcohol and tobacco  use assessment.  
b A complete physical examination includes a review of the following systems: head/neck/thyroid, eyes/ears/nose/throat, respiratory, cardiovascular,  
lymph nodes, abdomen, skin, musculoskeletal, and neurological. Breast, anorectal, and genital examinations will be performed when medically 
indicated.  After  screening, any clinically  significant abnormal  findings  in physical  examinations  not present  at screening  should be reported  as AEs.  
Radius Health, Inc.  
Confidential  Abaloparatide -SC 
Study  BA058 -05-020 Addendum   
  
c Vital signs include blood pressure (systolic and diastolic), temperature (oral), pulse rate, and respiratory rate. These will  be assessed following a 5- minute  
rest (seated or supine) and before blood sample collection. At visits when study drug is adminis tered at the site, vital sign assessments will be collected  
before the dose of study drug. Only blood pressure, pulse rate, and respiration rate are to be recorded one hour post -dose. Supine and standing blood 
pressure  measurements will be performed  at each visit during  the Treatment  Period.  
d Height  is to be measured in  the standing position  with shoes  off using a medical  stadiometer.  
e An ECG  will be recorded immediately  prior  to dosing  and one hour post-dose during the Treatment  Period.  
f All routine urinalysis will be performed on a sample freshly voided during the visit and sent to a central lab for microscopy if test is positive for  
microorganisms  via dipstick.  
g Serum  chemistry  will be measured  pre-dose at Visits  3, 4, 5 and 7. 
h Eighteen days before Day 1 of the Treatment Period (Visit 3), subjects who remain eligible for study participation will begin the first bone biopsy labeling 
procedure with administration of 150 mg demeclocycline 4 times daily for 3 days followed by a 12-d ay intermission, and then demeclocycline for 3 
additional  days at the same dose.  
i Approximately 23 to 26 days before Month 3 (Visit 5), subjects will begin the second bone biopsy labeling procedure with administration of 250 mg 
tetracycline  4 times  daily  for 3 days followed  by a 12-day intermission,  and then tetracycline for 3 additional  days at the same  dose.  
j Transiliac  crest bone biopsy 5- 8 days after last tetracycline dose. If an addendum subject terminates at or before Month 3, data will be collected  
according to the Addendum schedule for Month 3 (Visit 5) and study completion will occur at Month 4 (Visit 6).  The Sponsor Medical Monitor will 
decide if the  bone  biopsy will be included at Month  3 (Visit 5). 
k If the subject  reports  that a fracture has occurred,  remind  the subject  to bring  X-rays and any medical  reports  of the fracture to the  next clinic  visit.  
Documentation must  be obtained  on all new fractures  that occur  during  the study.  This documentation should  be maintained  in the source  documents.  
l The subject  will maintain a  diary  of her assessment  of local  tolerance after each injection  for one week  beginning on Day1,  Month 1 and Month  3. 
Subject will be instructed on completion of diary in the Pretreatment Period to include administration of medications for bone biopsy labeling 
procedure. The subject medication diary will be reviewed by study personnel at each study visit during the Treatment Period to ensure subject  
compliance.  
m AEs and SAEs will be recorded on the case report forms starting from the time of subject entry into the Screening Period (Visit 1) of the study (signed  
informed  consent)  until 30 days after the last dose of study  medication.  All AEs will be followed  until resolution  or stabilization.  Any SAEs  that occur  at 
any time after completion of the study, which are considered by the Investigator to be related to study treatment, must be reported to the Sponsor or its  
designee.  
n Vitamin D supplements are required to be administered daily from the Pretreatment Period until the end of the Treatment Period. Calcium will also be  
administered  daily,  with the exception of the days of administration  of demeclocycline and tetracycline  where  calcium  administration  will be withheld.  
 
  
13-Oct-2020  23:45:13  GMT+0000  Approval  
 
14-Oct-2020  12:40:35  GMT+0000  Approval  
 
 
30-Oct-2020  03:06:19  GMT+0000  Approval   
 
Signature  Page for RAD -CLIN- 002212 v1.0 
 
 
 
 
Signature  Page for RAD -CLIN- 002212 v1.0 
